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Summary  
Staphylococcus aureus (Sa) is a major human pathogen that secrets a great 
variability of virulence factors, which are very effective at subverting the human 
immune system. Phenol-soluble modulin (PSM) peptide toxins are one group of 
these secreted virulence factors, which highly contribute to Sa pathogenicity and are 
not only able to modulate immune cells, but also to lyse blood cells. Dendritic cells 
(DCs) are professional antigen presenting cells that link the innate and the adaptive 
immune response. Previously, the analysis of mouse bone marrow-derived DCs 
showed that PSMs have the ability to impair their protective functions in the immune 
system. However, the impact of Sa PSM peptides on human DCs was hitherto 
unknown. We therefore analyzed in this study the effect of PSMα3 on human 
monocyte-derived DC (moDC) maturation and functions, like cytokine production, 
antigen uptake, and T cell stimulatory capacity upon simultaneous treatment with 
either LPS (Toll-like receptor (TLR)4 ligand) or Sa cell lysate (TLR2 ligand).  
PSMs were able to penetrate the moDC cell membrane and enter the cytosol upon 
transient pore formation without cell lysis as shown by imaging flow cytometry. Upon 
simultaneous treatment with TLR ligands PSMs impaired DC functions, like reducing 
antigen uptake via clathrin-mediated endocytosis, modulating DC maturation, and 
preventing cytokine production. As a consequence, the adaptive immune response 
was affected by impaired T helper (Th) 1 differentiation. Instead the frequency and 
proliferation of regulatory T cells (Treg) with suppressive capacity was increased. 
Moreover, this Treg induction was also observed in an allogenic and autologous 
autoimmune disease setting, when CD4+ T cells from patients with Th1/Th17-
associated spondyloarthritis were co-cultured with PSMα3-treated mature DCs. 
Thus, PSMs from highly virulent Sa strains affect DC functions not only in the mouse, 
but also in the human system, by priming tolerogenic DCs (tDCs), which modulate 
the adaptive immune response and thereby probably increase the tolerance towards 
the bacteria. The ability of PSMα3 as a novel peptide to prime tDCs could be 
beneficial for clinical applications, like vaccination strategies. If this approach is 
feasible for treating autoimmune diseases in vivo, by either generating tDCs ex vivo 
or by the administration of PSMα3 has to be further investigated.  
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Zusammenfassung 
Staphylococcus aureus (Sa) ist ein bedeutender humaner Krankheitserreger, welcher  
eine große Vielfalt an Virulenzfaktoren sekretiert, die sehr effektiv zur Umgehung des 
humanen Immunsystems beitragen. Phenol-lösliche modulin (PSM) Peptidtoxine sind 
eine Gruppe dieser sekretierten Virulenzfaktoren, welche stark zur Pathogenität von 
Sa beitragen, da sie nicht nur imstande sind Immunzellen zu beeinflussen, sondern 
auch Blutzellen zu lysieren. Dendritische Zellen (DCs) sind professionelle Antigen-
präsentierende Zellen, welche die angeborene mit der erworbenen Immunantwort 
verknüpfen. Bislang konnte anhand der Analyse von aus Maus Knochenmark in vitro 
generierten DCs gezeigt werden, dass PSMs dazu fähig sind deren protektiven 
immunologischen Funktionen zu beeinträchtigen. Der Einfluss von Sa PSM Peptiden 
auf humane DCs war bisher unbekannt. Daher wurden in dieser Studie die 
Auswirkungen von PSMα3 nach gleichzeitiger Behandlung von humanen von 
Monozyten-abstammenden DC (moDC) mit LPS (Toll-ähnlicher Rezeptor (TLR)4 
Ligand) oder Sa Zelllysat (TLR2 Ligand) auf die Reifung, die Zytokinproduktion, die 
Antigenaufnahme und die Fähigkeit T Zellen zu stimulieren, untersucht.  
Durch bildgebende Durchflusszytometrie wurde hier gezeigt, dass PSMs imstande 
waren die Zellmembran von moDCs durch transiente Porenbildung zu penetrieren, 
um ins Zytosol zu gelangen, ohne dabei Zelltod zu induzieren. Durch die 
gleichzeitige Behandlung mit TLR Liganden und PSMα3 wurden die Funktionen von 
moDCs, wie folgt beeinträchtigt: verringerte Antigenaufnahme via Clathrin-
vermittelter Endozytose, veränderte DC Reifung und verminderte Zytokinproduktion. 
Dies führte, durch eine beinträchtige Differenzierung in T-Helfer (Th) 1 Zellen zur 
Beeinflussung der adaptiven Immunantwort. Stattdessen war die Anzahl und 
Proliferation von funktionell suppressiven regulatorischen T Zellen (Treg) erhöht. 
Darüber hinaus konnte diese Induktion an Tregs in allogenen und autologen 
Autoimmunkrankheitssettings beobachtet werden. Hierfür wurden CD4+ T Zellen von 
Patienten mit Th1/Th17-assoziierter Spondyloarthritis mit PSMα3-behandelten reifen 
DCs ko-kultiviert.  
Folglich beeinflussen PSMs von hochvirulenten Sa Stämmen nicht nur DCs in der 
Maus, sondern auch im humanen System. Dies erfolgt durch die Entstehung von 
tolerogenen DCs (tDCs), welche die adaptive Immunantwort verändern, was 
womöglich zur erhöhten Toleranz gegenüber dem Bakterium führt. Somit könnte 
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PSMα3 als ein neuartiges Peptid zur tDC Induktion verwendet werden, was für 
klinische Applikationen, wie Vakzinierungen, von Nutzen sein könnte. Ob dies durch 
eine ex vivo Generierung von tDCs oder durch Gabe von PSMα3 für die Therapie 
von Autoimmunkrankheiten in vivo möglich wäre, muss noch weiter untersucht 
werden.  
  
 Introduction  
 8
1. Introduction 
1.1 Dendritic cells 
In the 1970s Steinman and Cohn discovered the dendritic cell (DC) and described its 
unique role in the immune system (Steinman, 1974). DCs are rare (≈1 % of total 
hematopoietic cells) bone marrow-derived leukocytes that are crucial for the initiation 
and control of immune responses; they are found in blood, lymphoid and non-
lymphoid tissues (O’Keeffe et al., 2015). DCs are sentinels that continuously sample 
the environment for antigens (O’Keeffe et al., 2015). As cells of the innate immune 
system, DCs are able to recognize, take up and process extra- as well as intracellular 
antigens, thereby functioning as a bridge between the innate and adaptive immunity 
not only to initiate an acute inflammatory response but also to maintain self-tolerance 
(Collin & Bigley, 2018). The encounter with antigens leads to the maturation of DCs 
via the activation of pattern recognition receptors (PRRs) necessary for lymph node 
homing and T-cell activation (Hackstein & Thomson, 2004). The control of the 
immune response, directing tolerance or immunity, not only depends on the 
activation state of DCs but also on the existence of different types of DCs, each of 
which are specialized to respond to particular pathogens and to interact with specific 
subsets of T cells (Collin & Bigley, 2018; Collin, McGovern, & Haniffa, 2013; O’Keeffe 
et al., 2015). 
1.1.1 Human dendritic cell subsets 
DCs are a heterogeneous group of immune cells and the wide range of immune 
responses is orchestrated by three major DC subsets: plasmacytoid DCs (pDC) and 
the two conventional DCs (cDC), cDC1 and cDC2 (Breton et al., 2015; Collin & 
Bigley, 2018; Lewis & Reizis, 2012; Merad et al., 2013). The development into the 
different subsets is controlled by specific transcription and growth factors and is 
characterized by hierarchal differentiation from DC-specific progenitor cells (Collin & 
Bigley, 2018). The functionally distinct subsets differ in their surface molecule 
expression. Plasmacytoid DCs produce type I interferons (IFN) in response to viral 
infections and are identified by the expression of blood DC antigen (BDCA)-2/cluster 
of differentiation (CD)303 (Colonna, Trinchieri, & Liu, 2004) and their development is 
driven by the transcription factor E2-2 (Collin & Bigley, 2018). The two subsets of 
cDCs are distinguished by the expression of BDCA-1/CD1c and BDCA-3/CD141. 
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The CD1c+ DCs (cDC2) are the major human cDC subset, with a frequency of about 
1% of all mononuclear cells in the circulation and are dependent upon the 
transcription factors IRF4 and Notch2 (Collin & Bigley, 2018). They are pivotal for 
CD4+ T-cell priming (Collin et al., 2013; Jin et al., 2014; Leal Rojas et al., 2017) 
promoting T helper (Th)17- and Th2-biased immune responses to extracellular 
pathogens (Persson et al., 2013; Piccioli et al., 2007; Schlitzer et al., 2013). The 
CD141+ DCs (cDC1) only make up around 0.1% of mononuclear cells in the 
circulation and are therefore a fairly rare subset depending on IRF8 and BATF3 
(Collin & Bigley, 2018; Jongbloed et al., 2010; Piccioli et al., 2007) specialized in 
cross-presenting extra cellular antigens to activate CD8+ T cells and promote Th1 
responses (Bachem et al., 2010; Crozat et al., 2010; Jongbloed et al., 2010; Poulin et 
al., 2010; Robbins et al., 2008; Villadangos & Shortman, 2010). Despite the fact that 
DCs are present in almost all tissues in the whole body, only a small percentage of 
tissue cells are DCs. Hence it is hard to analyze small DC populations, especially in 
humans (Merad & Manz, 2009). The discovery of differentiating human blood 
monocytes into DCs (monocyte-derived DCs; moDCs) upon cytokine treatment made 
the DC research much easier. The key cytokine for this differentiation is granulocyte-
macrophage colony-stimulating factor (GM-CSF), but also other cytokines like 
Interleukin (IL)-4 and tumor necrosis factor (TNF) are needed (Merad & Manz, 2009). 
These moDCs have been widely used to study human DC biology and as a tool for 
vaccination strategies in various disease settings, e.g. as cancer therapy (P. Chen et 
al., 2015). 
1.1.2 Antigen uptake, processing and presenting by dendritic cells 
DCs are remarkable potent initiators of the adaptive immune response and have the 
unique ability to activate naïve T cells thereby shaping the immune response by 
driving differentiation into the distinct effector T-cell subsets (Mellman & Steinman, 
2001). DCs sample their surroundings and internalize, process, and present captured 
antigens on major histocompatibility complex (MHC) class I (MHC I) and MHC class 
II (MHC II) molecules. In order to initiate a sufficient T-cell response, DCs undergo 
functional and morphological changes, which is termed DC maturation.  
Immature DCs (iDCs) capture and take up antigens via three different mechanisms: 
macropinocytosis, receptor-mediated endocytosis and phagocytosis (Lanzavecchia, 
1996; Sallusto et al., 1995). Macropinocytosis, also referred to as fluid-phase 
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endocytosis, allows DCs to continuously take up very high levels of fluid phase 
volume containing possible antigens. This process is dependent on membrane 
ruffling by cytoskeletal rearrangement in order to form macropinosomes with a size of 
0.5 – 3 µm (Sallusto et al., 1995; Villadangos & Schnorrer, 2007). The other two 
routes of antigen capture and internalization are mediated by receptors found on the 
DC surface. iDCs have a high endocytic activity mediated by various receptors, like 
the macrophage mannose receptor (MMR/CD206), Fc receptors, the transferrin 
receptor and C-type lectin receptors (Cella et al., 1997; Lanzavecchia, 1996; Sallusto 
et al., 1995). Once an antigen has been bound to one of the receptors, the antigen-
receptor complex is internalized into clathrin-coated pits. Further, the cargo is either 
released at endosomal pH and the receptor recycles, e.g. the mannose-receptor. In a 
case involving Fc receptors, they are degraded in the endosomes as well (Cella et 
al., 1997). Lastly, DCs are able to internalize particles by phagocytosis. Phagocytosis 
is triggered by the encounter of extracellular particles with surface receptors, like Fc 
receptors and complement receptors (Mellman & Steinman, 2001). This process is 
used to take up whole microorganisms or apoptotic cells, which are labeled by 
antibodies or complement proteins (Cella et al., 1997; Lanzavecchia, 1996; Stuart & 
Ezekowitz, 2008).  
Antigens must be processed into peptides in order to be presented on MHC I 
molecules to activate CD8+ T cells or on MHC II to interact with CD4+ T cells (Sprent, 
1995). Endogenous antigens are presented on MHC I molecules after being 
degraded by the immunoproteasome in the cytosol, transported into the endoplasmic 
reticulum by the transporter associated with antigen processing (TAP) and loaded 
onto MHC I molecules (Muchamuel et al., 2009; Sprent, 1995; Villadangos & 
Schnorrer, 2007). In contrast, exogenous antigens following internalization are 
processed by proteases in the endosomal compartments and presented on MHC II 
molecules. Additionally, cDC1 are able to present exogenous antigens via MHC I 
molecules to CD8+ T cells, this is known as cross-presentation (Sprent, 1995; 
Villadangos & Schnorrer, 2007). It has been shown that TAP is involved in this 
process and that the phagosomes fuse with the ER providing the machinery for 
peptide loading. An indirect phagosome to cytosol pathway was also proposed, 
including processing of the peptides via the immunoproteasome (Palmowski et al., 
2006). 
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1.1.3 Maturation of dendritic cells 
Antigen presentation to T cells is highly controlled and is dependent upon a 
mechanism called DC maturation, which is initiated in the periphery. Immature DCs, 
the sentinels of the peripheral tissues are highly active antigen-capturing cells, with 
relatively low levels of MHC class II and costimulatory molecules on their cell surface. 
Therefore, iDCs have low stimulatory activity to activate naïve T cells, whereas 
mature DCs (mDCs) downregulate endocytic activity and are efficient T-cell 
activators (Mellman & Steinman, 2001; Tan & O’Neill, 2005). During infection or 
inflammation, DCs induce immunity after antigens are captured in the presence of 
activating stimuli like microbial products, inflammatory cytokines, or encounters with 
TNF receptors (Banchereau et al., 2000; Hackstein, Morelli, & Thomson, 2001; Tan & 
O’Neill, 2005). The absence of these signals leads to induction of tolerance. 
Activated and matured DCs undergo morphological changes, downregulate their 
endocytic capacity, and on the contrary upregulate costimulatory molecules like 
CD40, CD80 and CD86 and MHC II (Banchereau et al., 2000; Hackstein et al., 
2001). Furthermore, chemokine receptors are up-regulated, an important process for 
the migration to T-cell zones in secondary lymphoid organs (Ardeshna et al., 2000). 
The recognition of these activating stimuli, danger- or pathogen-associated molecular 
patterns (DAMPs, PAMPs), is mediated by various germline encoded PRRs 
triggering maturation. Immature DCs express a wide variety of PRRs, such as like 
toll-like receptors (TLR), nucleotide-binding oligomerization domain (NOD)-like 
receptors, RIG-I-like receptors and C-type lectin receptors (Kanneganti et al., 2007; 
Kawai & Akira, 2007; Matzinger, 2002; Medzhitov, 2001; Shaw et al., 2010; Tang et 
al., 2012; Villadangos & Schnorrer, 2007). The TLR family is one of the best-
characterized PRRs and is important for the control of DC maturation and cytokine 
production. TLRs are constitutively expressed and highly conserved throughout 
different species; so far 12 TLRs have been identified for the mammalian system. 
While recognizing a great variety of pathogens, TLRs contribute to the immune 
systems discrimination between self and foreign and thus make the innate immunity 
specific for microbial products (Kawai & Akira, 2011). TLRs are type I 
transmembrane receptors found at the cell surface (TLRs 1, 2, 4, 5, 6, 10, and 11) or 
intra-cellularly in endosomes (TLRs 3, 7, 8, and 9), possessing C-terminal leucine-
rich repeats important for recognition, a trans-membrane domain and a 
Toll/Interleukin-1R (TIR) signaling domain (Kawai & Akira, 2011; Manicassamy & 
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Pulendran, 2009). Compliant with their role in the immune system and in 
immunosurveillance, TLRs are highly expressed in tissues involved in immune 
function (e.g. spleen, peripheral blood), as well as in tissues exposed to the external 
environment (e.g. lung, gastrointestinal tract). Furthermore, these tissues also display 
the most diverse repertoire of TLRs (Zarember & Godowski, 2002). The distinct cell 
types in various tissues express varying levels of TLRs. Analysis of peripheral blood 
leukocytes showed that the greatest variety of TLRs are expressed by CD14+ 
mononuclear cells (Zarember & Godowski, 2002). However, the different TLR 
expression by the various cell types implies that specific roles exist in each 
population relating to the immunological function (Schreibelt et al., 2010; Zarember & 
Godowski, 2002). The distinct DC subsets also express different TLRs, which causes 
diverse effects when activated, reflecting their different functions in the immune 
response (Schreibelt et al., 2010). PDCs are important in viral infections and express 
TLR7 and TLR9, which are endosomal pattern recognition receptors, capable of 
sensing single-stranded RNA and double-stranded DNA, and TLR1 to some extent 
(Collin & Bigley, 2018; Schreibelt et al., 2010). Required for the efficient control of 
viral and intracellular antigens are cDC1s that express TLR3, 9 and 10. TLR3 and 
TLR10 are selectively expressed by this DC subset (Collin & Bigley, 2018). In 
common with monocytes, cDC2s express TLR2, 4, 5, 6, and 8; they highly respond 
to extracellular antigens (Collin & Bigley, 2018). Lastly, in vitro differentiated moDCs 
express all TLRs except for TLR9 and TLR10, however, not all to the same extent 
(Schreibelt et al., 2010). Upon the recognition of their ligands, TLRs dimerize thereby 
recruiting adaptor proteins such as myeloid differentiation primary response 88 
(MyD88), to TIR domain-containing adaptor protein (TIRAP), TIR-domain-containing 
adaptor-inducing interferon-β (TRIF), and TRIF-related adaptor molecule (TRAM) to 
the TLR TIR domains. Whereas most of the TLRs are MyD88-dependent, TLR3 
exclusively and TLR4 in part signal via TRIF. The interaction of the adaptor protein 
TIR domains with the TLR TIR domains leads to the activation of the Interleukin-1 
receptor-associated kinase (IRAK) family and TNF receptor associated factor 6 
(TRAF6), which in turn activates mitogen-activated protein kinases (MAPK) and 
transcription factors nuclear factor kappa-light-chain-enhancer of activated B-cells 
(NF-κb) and activator protein 1 (AP-1). These are important for inflammatory cytokine 
induction, type I interferons (IFN), and upregulation of costimulatory molecules and 
C-C chemokine receptor type 7 (Figure 1-1; (Manicassamy & Pulendran, 2009)). 
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Figure 1-1: TLR signaling pathways (Kawai & Akira, 2006) 
TLR are present on cell surfaces (e.g. TLR4) or localized in endosomes (e.g. TLR3). Both cell surface 
and endosomal TLRs induce downstream signaling, this leads to the induction of inflammatory 
cytokine and Type I IFNs expression. TLR3 exclusively signals via the MyD88- independent pathway, 
whereas TLR4 uses both pathways.  
1.1.4 Tolerogenic DCs  
Apart from inducing an efficient immune response, DCs are also crucial for 
maintaining immune tolerance against self-antigens in the steady-state. These 
tolerogenic DCs (tDCs) mediate tolerance by inducing T-cell anergy and deletion by 
insufficient stimulatory signals or by inducing the differentiation of regulatory T cells 
(Tregs) (Raker et al., 2015). Although the specific phenotype of tDCs and the 
molecular mechanism involved in tolerance induction by these cells are not entirely 
defined, especially as the group of tDCs is heterogeneous comprising naturally 
occurring and induced tDCs, it is thought that the maturation status plays a critical 
role (Gordon, 2014; Kushwah & Hu, 2011; Raker et al., 2015; Yoo & Ha, 2016). 
Whereas mDCs mediate immunity, iDCs, with a low MHC II and low costimulatory 
molecule phenotype and high production of anti-inflammatory cytokines, e.g., IL-10 
and TGF-ß, which possess critical immunoregulatory functions like 
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controlling/regulating the production of pro-inflammatory cytokines were suggested to 
maintain tolerance. These iDCs are poorly immunogenic and are therefore important 
in inducing tolerance under steady state conditions, after e.g. taking up apoptotic 
cells (Kushwah et al., 2009; Ouyang et al., 2011; Raker et al., 2015; Villadangos & 
Schnorrer, 2007). However, the maturation state alone does not define tDCs. Mature 
or semi-mature DCs were also found to induce tolerance (Raker et al., 2015; 
Villadangos & Schnorrer, 2007). Additionally, costimulatory as well as coinhibitory 
molecule expression, production of anti-inflammatory instead of pro-inflammatory 
cytokines and indoleamine-2,3-dioxygenase (IDO) expression characterizes the tDC 
phenotype (Raker et al., 2015). With the production of these molecules, tDCs have 
the potential to induce Treg expansion thereby impairing effector T-cell responses 
(Armbruster et al., 2016b; Ouyang et al., 2011; Raker et al., 2015; Schreiner et al., 
2013). Various pathogens and tumors are also able to induce tDCs and subsequent 
Treg differentiation thus escaping the immune response. Various pathogenic products 
from e.g. Candida albicans, Schistosoma mansoni and Vibrio cholerae are able to 
mediate this process and are therefore partially used for the production of 
immunosuppressive drugs, making tDCs a sufficient tool for therapeutic approaches 
(Maldonado & Andrian, 2010; Ouyang et al., 2011). 
1.2 T-cell activation and polarization 
Once DCs are activated they migrate to the draining lymph nodes to activate naïve T 
cells. This event requires multiple signals; signal 1 is the interaction of the antigen-
loaded MHC complex with the T-cell receptor. Signal 2 is the engagement of 
costimulatory or coinhibitory receptors and their ligands. Signal 3 is mediated by 
cytokines that are released by the mature DCs (Kambayashi & Laufer, 2014; Tai et 
al., 2018). CD4+ T cells differentiate into different T effector cell subsets, comprising 
of T helper (Th) 1, Th2, Th17, T follicular helper cells, and induced regulatory T cells 
(iTreg) all with distinct functions important for the regulation of immune responses. 
This differentiation, also known as polarization, is initiated upon the interaction of 
naïve CD4 T cells and antigen-bearing DCs expressing inflammatory cytokines. This 
process is further dependent upon, and mediated by, the cytokine milieu and the 
respective key transcription factor of the distinct subsets (Figure 1-2; (Park et al., 
2005; Zhou et al., 2009)). Each of these subsets produces effector cytokines that are 
important for its respective function. IL-12 induces the polarization of Th1 cells driven 
by the Th1 master transcription factor T-bet in concert with the transcription factor 
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signal transducer and activator of transcription 4 (STAT4). Th1 cells are 
characterized as IFN-γ producing Th cells, which mediate cellular immunity against 
intracellular microorganisms (Park et al., 2005; Szabo et al., 2003; Zhou et al., 2009). 
Th2 cells are induced by IL-4. They are further regulated and defined by STAT6 and 
GATA-binding protein 3 (GATA3) expression and are important for the production of 
IL-4, IL-5 and IL-13 that induces humoral immunity against extracellular pathogens 
(Park et al., 2005; Szabo et al., 2003; Zhou et al., 2009). Th17 differentiation is 
induced by TGF-β, IL-6 and IL-23 and is characterized by the expression of retinoic 
acid receptor-related orphan receptor-γt (RORγt) and STAT3. Th17 effector cells 
produce IL-17 and IL-22 and are also necessary for the clearance of extracellular 
pathogens (Z. Chen et al., 2007; Harrington et al., 2005; Zhou et al., 2009; Zou & 
Restifo, 2010). As well as inducing immunity, the differentiation of CD4+ T cells into 
Tregs regulates Th cell responses and is therefore crucial for maintaining immune 
homeostasis (Shevach, 2009; Vignali et al., 2008; Zhou et al., 2009). Tregs are 
induced by TGF-β, retinoic acid (RA), and IL-2 and characterized by the expression 
of the transcription factor forkhead box P3 (FoxP3). Tregs are further divided into 
natural Tregs (nTregs), which develop in the thymus and iTregs arising in the periphery, 
however, both subsets are important for immune tolerance (Schmitt & Williams, 
2013). This differentiation of naïve CD4+ T cells into the different effector T-cell 
subsets is not terminal. Plasticity allows the switch into one of the other subsets, with 
Th1 and Th2 being the most stable phenotypes (Zhou et al., 2009). 
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Figure 1-2: CD4
+
 T-cell polarization into the different Th subsets (Zou & Restifo, 2010) 
DCs activate naïve CD4+ T cells by engagement of the antigen-loaded MHC with the TCR. These 
naïve T cells differentiate into the different Th subsets (Th1, Th2, Th17 or Treg), which is dependent on 
the local cytokine milieu and driven by the key master transcription factors of each Th cell subset.   
1.3 Staphylococcus aureus phenol-soluble modulin peptides 
Staphylococcus aureus (Sa), a commensal Gram-positive bacterium, is a major 
human pathogen and a leading cause of morbidity and mortality. Multi-drug 
resistance and enhanced virulence of Sa constitutes a health threat, especially the 
community-associated methillin-resistant Sa (CA-MRSA) strains, such as USA300. 
The wide variability of secreted or cell surface-associated virulence factors and the 
resulting different strategies to evade the host’s immune system are responsible for 
the high pathogenicity of Sa (Coates et al., 2014; DuMont & Torres, 2014; M. Miller et 
al., 2009; Peschel & Otto, 2013). Phenol-soluble modulins (PSMs), originally 
discovered in Staphylococcus epidermidis (Mehlin et al., 1999) are a family of 
secreted short cytolytic peptide toxins produced by highly virulent Staphylococci that 
greatly contribute to the pathogenesis of Sa (Chatterjee et al., 2013; Cheung et al., 
2014; R. Wang et al., 2007). Two types of PSMs with a total of seven members are 
distinguished according to their length, which all share an amphipathic α-helical 
structure, a formylated N-terminus, but have limited sequence similarity (Figure 1-3): 
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the α-type PSMs (PSMα1-4 and δ-toxin; ~20–25 AA) and the β-type PSMs (PSMβ1-
2; ~44 AA) (Peschel & Otto, 2013; R. Wang et al., 2007).  
 
Figure 1-3: Amino acid sequences of the seven PSM family members (R. Wang et al., 2007) 
PSMs are capable of lysing many eukaryotic cell types and stimulating inflammatory 
responses. Due to their surfactant-like properties, they are important in biofilm 
formation, and are thus key mediators in Sa pathogenesis (Chatterjee et al., 2013; 
DuMont & Torres, 2014; Grumann et al., 2014; M. Miller et al., 2009; Peschel & Otto, 
2013). CA-MRSA strains secrete by far the highest amounts of PSM peptides. 
However, as the peptides also trigger inflammatory responses, the production is 
under tight control of the quorum-sensing accessory gene regulator system. This 
ensures expression only at times of high bacteria density and results in efficient 
evasion of the immune system (Cheung et al., 2014). Notably, not all PSMs equally 
contribute to Sa pathogenesis. The PSMα peptides harbor essential functions and 
are the most potent PSMs with regard to cytolysis. PSMα peptides highly contribute 
to the virulence and disease manifestation of CA-MRSA (Cheung et al., 2014; 
Peschel & Otto, 2013; R. Wang et al., 2007). 
1.3.1 The effect of phenol-soluble modulins on the immune system 
PSM peptide toxins have multiple effects on immune cells, thereby manipulating the 
immune response. Especially the PSMα peptides, with their high cytolytic activity 
efficiently contribute to immune evasion. At nanomolar concentrations, PSMs recruit 
and activate human neutrophils via binding to the N-formyl peptide receptor 2. At 
higher concentrations, several PSMαs show cytolytic activity with the ability to lyse 
erythrocytes, monocytes, and human neutrophils. This takes place after phagocytosis 
by membrane disruption and perturbation in a receptor-independent fashion and 
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eliminates the cellular innate host defense (Cheung et al., 2011; Forsman et al., 
2012; Kretschmer et al., 2010; R. Wang et al., 2007). However, not only the innate 
immune response but also the adaptive immune system is affected by modulation of 
DC functions. PSMs affect mouse bone marrow-derived DCs (BM-DCs) by acting as 
chemoattractants, inhibiting clathrin-mediated endocytosis, which is essential for 
antigen uptake. Further the secretion of pro-inflammatory cytokines is suppressed. In 
contrast, IL-10 production is upregulated by increased phosphorylation of the MAPK 
p38. This results in a reduced Th1 immune response and the frequency of Treg cells 
is increased, further contributing to immune evasion of Sa (Armbruster et al., 2016b). 
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1.4 Research objectives 
Sa by means of the secretion of PSM peptide toxins is able to evade the innate host 
defence by lysing neutrophils and monocytes after phagocytosis. Sa is a major 
human pathogen and as DCs act as link between the innate and adaptive immune 
response, DC modulation might play an important role in Sa pathogenesis. Indeed, 
PSMs also affect the adaptive immune response in the mouse by modulating 
dendritic cell maturation and functions, like antigen uptake and cytokine secretion, 
leading to a reduced Th1 immune response and to an increased frequency of Tregs. 
Herein, we addressed the question if Sa-derived PSM peptides also affect human 
dendritic cells and their ability to activate T cells. Human monocyte-derived DCs were 
simultaneously treated with TLR ligands and PSMα3. The expression of 
costimulatory, as well as coinhibitory molecules, antigen uptake and T cell 
stimulatory capacity was analyzed by flow cytometry. Cytokine secretion by moDCs 
or in co-culture with and therefore upon interaction with T cells was assessed by 
performing enzyme-linked immunosorbent assays or bead-based immunoassays. 
Antigen uptake and PSM uptake was further evaluated by imaging flow cytometry. If 
Sa PSM peptides also show the ability to prime tolerogenic human DCs, it could be 
beneficial for clinical use of the peptide. Therefore, the ability of the treated moDCs to 
activate and prime T cells in an autoimmune disease setting was additionally 
assessed in a mixed lymphocyte reaction and analyzed by flow cytometry.  
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2. Material and Methods 
2.1 Research Subjects 
Buffy coats from healthy volunteers were obtained from the ZKT Tübingen GmbH. 
Fresh blood was obtained from healthy volunteers with informed consent. This was 
approved by the ethical review committee of the medical faculty of the Eberhard-
Karls-University of Tübingen with the project number 633/2012BO2. Blood from 
patients with Th17-associated autoimmune diseases were obtained from the division 
of Rheumatology, Department of Internal Medicine II, University Hospital Tübingen. 
This was approved by the ethical review committee of the medical faculty of the 
Eberhard-Karls-University of Tübingen with the project number 046/2015BO2.  
2.2 Reagents 
Formylated PSM peptides (PSMα2, PSMα3, δ-Toxin) were synthesized at the 
Interfaculty Institute of Cell Biology, Department of Immunology, University of 
Tübingen. FITC-labeled PSMα2 was synthesized at the Group of Hubert Kalbacher, 
Interfaculty Institute of Biochemistry, University of Tübingen. Sa cell lysate (Sa 
lysate) containing lipopeptides and specifically activating TLR2 was prepared from a 
protein A-deficient Sa mutant strain (SA113) and provided by Andreas Peschel, 
Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen. 
The AlexaFluor647-conjugated model antigen Ovalbumin (OVA) was purchased from 
Invitrogen.  
2.3 Isolation of peripheral blood mononuclear cells 
Buffy coats or fresh blood was diluted with Dulbecco’s PBS (Life Technologies) 
(Buffy Coats 1:7 blood: PBS; Fresh blood 1:1 blood: PBS). Peripheral blood 
mononuclear cells (PBMCs) were obtained by density gradient centrifugation at 2000 
rpm for 20 min at room temperature with 35 mL cell suspension stacked on 15 mL 
Biocoll separation solution (Biochrom). The interphase containing the PBMCs was 
abstracted and washed twice with PBS. PBMCs were further used to generate 
human moDCs and for the isolation of naïve CD4+ T cells and CD4+ T cells.  
2.4 Generation of human monocyte-derived DCs  
PBMCs were plated in a tissue-treated 6-well plate (6x106 cells per well) in DC 
medium (RPMI1640 (Merck), 10% FBS (Sigma), 2 mM L-Glutamine (Life 
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Technologies), 100 U/mL Penicillin-Streptomycin (Life Technologies), 1x non-
essential amino acids (Merck), 1 mM sodium pyruvate (Merck) and 50 µM 2-
mercaptoethanol (Roth)) and incubated for 1 h at 37°C, 5% CO2. After that, wells 
were washed with medium and PBS discarding the non-adherent cells. 3 mL/well DC 
medium containing 50 ng IL-4 and 100 ng GM-CSF (both from Miltenyi) was added to 
the remaining cells. Cells were incubated for 6 d at 37°C, 5% CO2. Cytokines were 
again added on day 2 and day 4. At day 6 the cells were used for the following 
experiments. The purity of the moDC culture was always >90% of lymphocytes. 
2.5 Stimulation of human monocyte-derived DCs 
For stimulation moDCs were seeded in non-tissue culture treated 96-well or 48-well 
plates (cell number see the particular experiment) and treated with 3 µg/mL Sa lysate 
or 100 ng/mL LPS in combination with or without PSMα3 (10 µM) and incubated for 6 
h, 24 h or 48 h, if not indicated differently for the individual experiments.   
2.6 Cytokine/ indolamin-2,3-Dioxygenase production by moDCs 
MoDCs (2,5x105) were seeded in a 96-well plate and treated with Sa lysate or LPS in 
combination with or without PSMα3. Supernatants were collected after 6 h, 24 h or 
48 h and analyzed for TNF, IL-10, IL-12 and IDO production, respectively. Cytokines 
and IDO in the supernatants were determined by sandwich ELISA (eBioscience 
(TNF, IL-10, IL-12), R&D Systems (IDO)) according to the manufacturer’s 
instructions. 
2.7 Dendritic cell surface molecule expression analysis by flow 
cytometry  
For moDC (CD11c+HLA-DR+) surface marker analysis of costimulatory and 
coinhibitory molecules, moDCs (2x105) were seeded in a 96-well plate and treated 
with Sa lysate and LPS with or without PSMα3 or with only PSMα3 for 6 h 
(costimulatory) or 24 h (costimulatory and coinhibitory). Cells were removed from the 
plate using Accutase (Sigma-Aldrich) and treated with IgG from human serum (1µg of 
human IgG per 100,000 cells; Sigma-Aldrich) for 20 min at room temperature to 
avoid unspecific binding via Fc receptors.  
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Table 2-1: Panel for the analysis of DC surface markers 
Panel Antigen Fluorochrome Clone Company 
DC 
costimulatory 
Molecules           
HLA-DR BV650 L243 BioLegend 
  CD11c  APC 
MJ4-
27G121 Miltenyi 
  CD40 FITC 5C3 BioLegend  
  CD83 PE/Dazzle594 HB15e BioLegend 
  CD80  PE/Cy7 2D10 BioLegend 
  CD86 BV605 IT2.2 BioLegend 
  Zombie Aqua   
DC coinhibitory 
Molecules           
HLA-DR  BV650 L243 BioLegend 
  CD11c  PE/Cy7 Bu15 BioLegend 
   PD-L1  PE 29E.2A3 BioLegend 
   PD-L2  PE MIH18 BioLegend 
   ILT3  PE ZM4.1 BioLegend 
      Zombie Aqua   BioLegend 
 
Cells were stained according to Table 1 for 20 min at 4°C. Zombie Aqua was used to 
exclude dead cells. FACS buffer (PBS containing 1% FBS, 2 mM EDTA (Merck) and 
0.09% NaN3 (Sigma-Aldrich)) was used for all incubations and washing steps. At 
least 50,000 cells were acquired using a LSR Fortessa flow cytometer (BD 
Biosciences) with the DIVA software (BD Biosciences) and were further analyzed 
using FlowJo 10.4.2 software (Tree Star). 
2.8 Phospho flow cytometry 
For the experiments analyzing phosphorylation of p38 and NF-κB, moDCs (2x105) 
were seeded in a 96-well plate and treated with LPS with or without PSMα3 or with 
only PSMα3 for 30 min or 1 h. Cells were removed from the plate using Accutase and 
incubated with IgG from human serum (1µg of human IgG per 100,000 cells) for 20 
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min at room temperature to avoid unspecific binding via Fc receptors. Cells were 
stained with the antibodies listed in Table 2, where Zombie Aqua was used to 
exclude dead cells and the fluorochrome conjugated HLA-DR and CD11c were used 
for extracellular staining, which were incubated for 20 min at 4°C.  
Table 2-2: Antibody panel for phospho flow cytometry  
Panel Antigen Fluorochrome Clone Company 
Phospho flow           
HLA-DR PE L243 BD Biosciences 
  CD11c  APC/Cy7 Bu15 BioLegend 
  
p-NF-κB p65 
(Ser536) - 
93H1 
Cell Signaling   
  
p-p38 MAPK 
(Thr180/Tyr182) - 
12F8 
Cell Signaling  
  Rabbit IgG  DyLight649  
  
Jackson 
ImmunoResearch 
   Zombie Aqua  BioLegend 
 
To detect intracellular phospho-p38 (p-p38) and phospho-NF-κB (p-NF-κB) cells 
were fixed with 2% paraformaldehyde (VWR) in PBS, permeabilized with 90% 
freezing methanol (Applichem) overnight and stained with the primary Abs to p-p38 
MAPK or phospho-NF-κB p65 for 1 h in the dark at room temperature followed by 
staining with secondary DyLight649-conjugated AffiniPure Goat At-Rabbit IgG 
antibody for 15 min at 4°C. PBS with 0.5% BSA (Biomol) was used for incubation and 
washing steps of intracellular antibody staining. At least 50,000 cells were acquired 
using a Canto-II (BD Biosciences) with DIVA software (BD Biosciences) and were 
further analyzed using the FlowJo 10.4.2 software (Tree Star). 
2.9 Measurement of antigen uptake by flow cytometry or 
multispectral imaging flow cytometry 
MoDCs (5x105) were seeded in a 48-well plate and treated for 24 h with Sa lysate or 
LPS with or without PSMα3 or with only PSMα3 prior to the incubation with OVA-
AlexaFluor647 (5 µg/mL, Invitrogen) together with PSMα2 FITC (0.5 µM) for 30 min 
at 37°C, 5% CO2. Unspecific binding of OVA/PSMα2 was assessed by incubating the 
cells on ice. Cells were washed twice with ice-cold PBS containing 2% FBS. 
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Subsequently, cells were blocked with IgG from human serum for 20 min at room 
temperature and stained according to Table 3 for flow cytometry analysis and Table 4 
for imaging flow cytometry analysis for 20 min at 4°C.  
Table 2-3: Antibody panels for antigen uptake analysis at the flow cytometry and the Image-Stream mkII 
Panel Antigen Fluorochrome Clone Company 
Antigen uptake 
FACS           
HLA-DR BV650 L243 BioLegend 
  CD11c  PE/Cy7 Bu15 BioLegend 
   Zombie Aqua  BioLegend 
Antigen uptake 
ISX           
HLA-DR PE L243 BD Biosciences 
  CD11c  PE/Cy7 Bu15 BioLegend 
   DAPI  Sigma 
 
At least 50,000 cells were acquired using a LSR Fortessa flow cytometer (BD 
Biosciences) with the DIVA software (BD Biosciences) and further analyzed using the 
FlowJo 10.4.2 software (Tree Star). Images of 10,000 living moDCs were acquired 
using the Image-Stream mkII (ISX; Amnis) with the INSPIRE instrument controller 
software. The data were analyzed using the IDEAS analysis software (Merck 
Millipore). 
2.10 Lactate dehydrogenase release 
MoDCs (2x105) were seeded in a 96-well plate and treated with Triton X100 (1%; 
Sigma-Aldrich), DMSO (2%, Fluka), PSMα2 (10 µM), PSMα3 (2.5 µM, 5 µM, 7.5 µM, 
10 µM), δ-Toxin (10 µM) or OVA (10 µg, Sigma-Aldrich) for 10 min at 37°C, 5% CO2. 
Supernatants were used for the analysis of lactate dehydrogenase (LDH) release 
using the Cytotoxicity Detection Kit (Roche) according to the manufacturer’s 
instructions. Absorbance was measured at 492 nm and 620 nm over a period of 1 h 
with an interval of 5 min using the Spark 10M microplate reader (Tecan). Cell death 
was determined by staining the cells with 7-aminoactinomycin D (7-AAD, Biomol) and 
acquiring on a Canto II flow cytometer with the DIVA software.  
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2.11 T-cell assay/ allogenic T-cell assay  
MoDCs (5x104) were seeded in a 96-well plate and treated with Sa lysate or LPS 
with or without PSMα3 or with only PSMα3 for 24 h. For some experiments moDCs 
were pre-treated with the IDO Inhibitor 1-Methyl-D-tryptophan (1-DMT; 200 µM) or 
with a human IL-4 Rα blocking antibody (R&D Systems) for 1 h prior to the 
stimulation. The human IL-4 Rα antibody was again added on day 2 of the co-culture. 
Human naïve CD4+ T cells were isolated from PBMCs using the MojoSort™ Human 
CD4 Naïve T Cell Isolation Kit (BioLegend) according to the manufacturer’s 
instructions. For the allogenic T cell assay CD4+ T cells from patients were isolated 
using CD4 Microbeads (Miltenyi Biotech) according to the manufacturer’s 
instructions. For the magnetic cell separation, a LS column (Miltenyi Biotech) was 
placed into the QuadroMACS Separator (Miltenyi Biotech) and rinsed with MACS 
buffer (PBS containing 0,5% BSA (Biomol) and 2 mM EDTA). The cell suspension 
was applied to the column, and the column was washed three times with 3 mL MACS 
buffer. The untouched naïve CD4+ T cells were collected in the flow through. The 
purity of isolated (naïve) CD4+ T cells was always ≈85%. The naïve CD4+ T cells 
were labeled with Carboxyfluorescein succinimidyl ester (CFSE; 5 µM, BioLegend) 
according to the manufacturer’s instructions. 2x105 T cells diluted in 100 µL T cell 
medium (RPMI1640 (Merck), 10% FBS (Sigma), 2 mM L-Glutamine (Life 
Technologies), 100 U/mL penicillin-streptomycin (Life Technologies), 1x non-
essential amino acids (Merck), 1 mM sodium pyruvate (Merck), 10 mM HEPES 
(Biochrom) and 50 µM 2-mercaptoethanol (Roth)) were added to the moDCs. To 
investigate whether secreted factors from DCs upon PSM-treatment mediate Treg 
priming, T cells were co-cultured with untreated moDCs adding conditioned medium 
from LPS or LPS + PSMα3 stimulated DCs. In a third assay moDCs treated as 
described above were splitted using Accutase (Sigma-Aldrich) for 5 min at room 
temperature and again sowed with either fresh or conditioned DC medium (TLRL or 
TLRL + PSMα3). In some conditions, DC were fixed with 1% paraformaldehyde for 
10 min at 4°C to address the impact of newly secreted factors on Treg priming by 
DCs. 3-4 d after co-culture T cells were blocked with IgG from human serum for 15 
min at room temperature and subsequently stained extracellularly with the antibodies 
listed in Table 5 for 20 min at 4°C. For intracellular staining, cells were fixed and 
permeabilized with the Foxp3/ Transcription Factor Staining Buffer Set 
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(eBiosciences), blocked and stained with the intracellular antibodies listed in Table 5 
for 45 min at 4°C.  
Table 2-4: Antibody panel for T-cell subset analysis 
Panel Antigen Location  Fluorochrome Clone Company 
T cells           
CD3 Extracellular Pacific Blue SK7 BioLegend 
  CD4 Extracellular APC-Vio770 REA623 Miltenyi 
 CD25 Extracellular PE-Cy7 BC96 eBioscience 
 CD45RA Extracellular BV605 HI100 BioLegend 
 CD127 Extracellular PE eBioRDR5 eBioscience 
 FoxP3 Intracellular AlexaFluor647 259D BioLegend 
 T-bet Intracellular PE/Dazzle594 4B10 BioLegend 
 GATA3 Intracellular PerCP/Cy5.5 16E10A23 BioLegend 
 RORγt Intracellular BV650 Q21-559 BD Biosciences 
   CFSE  BioLegend 
   Zombie Aqua  BioLegend 
    
FACS buffer was used for all incubations and washing steps for the extracellular 
staining, and 1x permeabilization buffer (Foxp3/ Transcription Factor Staining Buffer 
Set (eBiosciences)) was used for all incubations and washing steps for the 
intracellular staining. At least 70,000 cells were acquired using an LSR Fortessa flow 
cytometer (BD Biosciences) with the DIVA software (BD Biosciences) and were 
further analyzed using FlowJo 10.4.2 software (Tree Star). 
2.12 Autologous T- cell assay  
CD14+ cells from PBMCs of patients with Th17-associated autoimmune diseases 
were isolated by MACS using CD14 MicroBeads (Miltenyi Biotech) and plated in a 
tissue-treated 6-well plate (1.3x106 cells per well) in DC medium containing 50 ng IL-
4 and 100 ng GM-CSF for 6 d to generate moDCs. The remaining CD14- cells were 
frozen at -80°C in RPMI1640 supplemented with 20 % FBS and 10% DMSO. After 6 
d moDCs (5x104) were seeded in a 96-well plate and treated with LPS with or without 
PSMα3 for 24 h. The CD14- cells were thawed and used to isolate CD4+ T cells by 
MACS with CD4 MicroBeads (Miltenyi Biotech). The CD4+ T cells were labeled with 
CFSE (5 µM) according to the manufacturer’s instructions and 2x105 T cells diluted in 
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100 µL T-cell medium were added to the moDCs. 3-4 d after co-culture T cells were 
stained as above (see Table 5) and iTregs (CD3
+CD4+CD127-CD25hiCD45RA-
FoxP3hi) were analyzed by flow cytometry using an LSR Fortessa flow cytometer (BD 
Biosciences) with the DIVA software (BD Biosciences) and were further analyzed 
using FlowJo 10.4.2 software (Tree Star). 
2.13 Cytokine production in the moDC-T-cell co-culture 
50 µL cell culture supernatants from the T cell assay were collected on day 1, 2 and 
3 and cytokine production from 15 µL was analyzed by performing bead-based 
immunoassays in a 96-well plate (LEGENDplex human B cell Panel (13-Plex) and 
LEGENDplex Free Active/Total TGF-β1 (BioLegend)) according to the 
manufacturer's instructions, using the Lyric flow cytometer with autosampler (BD 
Bioscience).    
2.14 T-cell suppression assay 
MoDCs (2x105) were seeded in a 48-well plate and stimulated with LPS and PSMα3 
for 24 h. Human CD4+ T cells were isolated from PBMCs using the human CD4 
MicroBeads Kit (Miltenyi) according to the manufacturer’s instructions using LS 
columns. 8x105 T cells were added to the stimulated moDCs and cultured for 4 d at 
37°C, 5% CO2. T cells were stained according to Table 6, where DAPI (16,7 ng/mL) 
was used to exclude dead cells. Tregs (CD4
+CD127-CD25hiCD45RA-) were purified by 
FACS sorting using an ARIA IIu cell sorter (BD Bioscience).  
Table 2-5: Panel for sorting regulatory T cells  
Panel Antigen Fluorochrome Clone Company 
Treg Sort            
  CD4 APC-Vio770 REA623 Miltenyi 
  CD25 PE-Cy7 BC96 eBioscience 
  CD45RA PerCP HI100 BioLegend 
  CD127 PE eBioRDR5 eBioscience 
   DAPI  Sigma 
 
CD4+ T cells, isolated from PBMCs from a different donor using the CD4 MicroBeads 
Kit (Miltenyi) were used as T effector (Teff) cells. The Teffs were labeled with CFSE (5 
µM), and 8x104 cells were seeded in a 96- well plate in T-cell medium together with 
the indicated numbers of sorted Tregs. For T-cell activation of the Teffs Dynabeads 
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(Human T-Activator CD3/CD28 Proliferation; Gibco) were added according to the 
manufacturer's instructions. The proliferation of Teffs was assessed after 3 d by 
analyzing the CFSE signal by flow cytometry. Dead cells were excluded by staining 
the cells with Zombie Aqua. 20,000 cells were acquired at the Canto II with the DIVA 
software (BD Biosciences) and were further analyzed using the proliferation tool in 
FlowJo 10.4.2 software (Tree Star). 
2.15 Statistical analysis 
Statistical analysis was performed using the GraphPad Prism 7.0a software 
(GraphPad, San Diego, CA). Statistical differences were determined using one-way 
ANOVA with Turkey’s posttest or an unpaired student's T-test in case data were 
normally distributed (Shapiro-Wilk normality test). Otherwise, data were analyzed 
using the Kruskal-Wallis nonparametric test. The differences were considered as 
statistically significant if p < 0.05 (*), p < 0.005 (**), p < 0.001 (***), or p < 0.0001 
(****). 
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3. Results 
3.1 PSMs modulate DC maturation 
DCs are key regulators of the adaptive immune response. However, in order to 
successfully activate T cells, DCs have to undergo phenotypical and morphological 
changes, known as maturation (Banchereau et al., 2000). This includes the 
upregulation of maturation markers (e.g., CD83 and the human MHC II molecule 
Human Leukocyte Antigen – DR isotype (HLA-DR)), costimulatory (e.g., CD80, 
CD86, CD40), as well as coinhibitory molecules (e.g., Programmed death-ligand 
(PD-L)1, PD-L2 or Immunoglobulin-like transcript (ILT)3). To address whether the 
Sa-secreted peptide toxin PSMα3 has an effect on DC maturation, moDCs were 
treated with either the TLR2 ligand Sa lysate (Schreiner et al., 2013) or the TLR4 
ligand LPS in combination with, and without, PSMα3. MoDCs were characterized as 
living CD11c+HLA-DR+ leukocytes (Figure 3-1 A) and surface marker expression 
was assessed by flow cytometry after 6 h or 24 h. Except for CD80 after 6 h, the 
expression of all surface markers increased after 6 h or 24 h upon TLR ligand (TLRL) 
treatment compared to untreated cells (Figure 3-1 B-D); this indicated DC 
maturation. Co-treatment with PSMα3 for 6 h showed a slight but not significant 
increase of CD83 and CD86 and a significant higher expression of HLA-DR 
compared to the treatment with TLRLs alone (Figure 3-1 B). On the contrary, CD40 
was significantly less expressed on TLR4 treated mDCs when co-treated with 
PSMα3 for 6 h or 24 h (Figure 3-1 B, C). Likewise, CD80 expression was hampered 
on TLR4-stimulated mDCs when treated in combination with PSMα3 for 24 h (Figure 
3-1 C). No significant results were obtained from the analysis of the coinhibitory 
molecules PD-L1, PD-L2 and ILT3 after 24 h; however, PSMα3 seems to inhibit the 
up-regulation of PD-L1 expression on TLR4-treated mDCs (Figure 3-1 D). In 
conclusion, PSMα3 affects surface molecule expression of TLRL-treated moDCs by 
enhancing early costimulatory molecule and HLA-DR expression while 
simultaneously inhibiting CD80 and CD40 upregulation upon TLR4 stimulation.  
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Figure 3-1: PSMs modulate DC maturation by affecting surface molecule expression of TLRL-treated 
moDCs (from Richardson et al., 2018) 
(A) Gating strategy: moDCs were characterized as living CD11c+HLA-DR+ leukocytes. (B-D) MoDCs were treated 
with Sa lysate (Sa) or LPS with, and without, PSMα3 for 6 h (B) or 24 h (C, D) and analyzed by flow cytometry. 
The expression of the indicated costimulatory (B, C) and inhibitory molecules (D) was determined as mean 
fluorescence intensity (MFI). The MFI of the respective marker expression is shown in the bar graphs as fold 
change of untreated cells (left). The graphs represent n≥3 independent experiments (mean ± SEM) performed in 
triplicates. Representative histogram overlays (right) of HLA-DR and CD40 after 6 h (B), CD80, CD40 (C), and 
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PD-L1 (D) after 24 h. *p < 0.05, **p < 0.005 or ****p < 0.0001, one-way ANOVA with Turkey’s posttest or Kruskal-
Wallis with Dunn’s posttest.  
3.2 Cytokine secretion of TLR4-treated moDCs is impaired by 
PSMs 
Upon activation and maturation DCs express cytokines, important for T-cell activation 
and priming (Blanco et al., 2008a). Previously, it was shown that PSMα3 inhibits pro-
inflammatory cytokine secretion of mouse bone-marrow derived DCs (BM-DCs) after 
stimulation with various TLRLs and conversely induced the expression of IL-10, 
thereby manipulating the immune response (Armbruster et al., 2016b). To investigate 
if PSMα3 has similar effects on human DCs, cell culture supernatants from TLRL-
treated moDCs in combination with, and without, PSMα3 were analyzed after 6 h for 
the pro-inflammatory cytokine TNF (Figure 3-2 A) and after 24 h for the pro-
inflammatory cytokine IL-12 (Figure 3-2 B) or the anti-inflammatory cytokine IL-10 
production (Figure 3-2 C). 
 
 
Figure 3-2: PSMs impair cytokine secretion by TLR4-treated moDCs (adapted from Richardson et al., 
2018) 
MoDCs were treated with Sa lysate (Sa) or LPS with, and without, PSMα3 for 6 h (A) or 24 h (B, C). Cytokine 
production of TNF (A), IL-12 (B) and IL-10 (C) was analyzed in the cell culture supernatants by sandwich ELISA. 
The graphs represent n ≥10 independent experiments (mean ±SEM) performed in triplicates. *p < 0.05 or **p < 
0.005, one-way ANOVA with Turkey’s posttest or Kruskal-Wallis with Dunn’s posttest. 
Treatment with TLRLs induced overall secretion of pro- and anti-inflammatory 
cytokines compared to untreated moDCs (Figure 3-2 A-C), except for IL-12 in TLR2-
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treated cells (Figure 3-2 C). PSMα3 had no effect on pro- or anti-inflammatory 
cytokine secretion of moDCs treated with the TLR2 ligand Sa lysate (Figure 3-2). 
However, the LPS-induced secretion of TNF, IL-12 and also IL-10 was significantly 
inhibited when cells were co-treated with PSMα3 (Figure 3-2). In summation, PSMα3 
impairs pro- as well as anti-inflammatory cytokine secretion by TLR4-treated mDCs.  
3.3 PSMs dampen phosphorylation of NF-κB and p38 in TLR4-
treated moDCs 
The maturation of DCs is induced by engagement of stimuli with various PRRs, like 
TLRs, which activate signaling pathways regulating e.g. cytokine production. The 
activation of these signaling pathways is often mediated by the phosphorylation of 
certain proteins, including NF-κB and p38 MAPK. The p38 MAPK signaling pathway 
is connected to DC maturation and to cytokine production and NF-κB is a 
transcription factor involved in regulating inflammatory responses (Nakahara et al., 
2006). To investigate whether these signaling pathways are affected and responsible 
for the impaired cytokine production in TLR4-treated cells in the presence of PSMα3, 
DCs were treated with LPS in the presence and in the absence of PSMα3 for 30 min 
or 60 min and phosphorylation of NF-κB (p-NF-κB; Figure 3-3 A, B) and p38 (p-p38; 
Figure 3-3 C, D) was determined via flow cytometry analysis. The treatment with 
PSMα3 alone showed no changes in p-NF-κB (Figure 3-3 A, B heatmap) or p-p38 
(Figure 3-3 C, D heatmap) after 30 min or 60 min compared to untreated moDCs. 
LPS treatment, however, showed an increase in phosphorylation in both NF-κB and 
p38. The phosphorylation of NF-κB was increased 3.4 fold after 30 min of LPS 
treatment and 2.5 fold increased after 60 min of stimulation compared to untreated 
cells (Figure 3-3 A, B heatmap). The phosphorylation of p38 did not increase as 
much, with only a 2.95 fold increase after 30 min (Figure 3-3 C heatmap) of LPS 
treatment and 1.9 fold after 60 min (Figure 3-3 D heatmap). The presence of PSMα3 
in TLR4-treated moDCs showed a reduced phosphorylation of both NF-κB and p38. 
Simultaneous stimulation of LPS with PSMα3 had no effect on NF-κB 
phosphorylation after 30 min compared to LPS-treated moDCs (3.37±1.1 vs. 
3.1±1.18) which was analyzed in 4 individual donors (Figure 3-3 A). 
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Figure 3-3: PSMs dampen the phosphorylation of NF-κB and p38 LPS-Treated moDCs (adapted from 
Richardson et al., 2018) 
MoDCs were treated with LPS with, and without, PSMα3 or with only PSMα3 for 30 min (A, C) or 60min (B, D). 
Phosphorylation of NF-κB (p65 Ser536) and p38 (Thr180/Tyr182) was analyzed in CD11c+HLA-DR+ cells. 
Representative histogram overlays of p-NF-κB after 30 min (A) or 60 min (B) and of p-p38 after 30 min (C) or 60 
min (D). The heat map shows the fold-change of p-NF-κB (A, B) or p-p38 (C, D) normalized to untreated DCs 
(unst.). The graphs show the fold change of p-NF-κB (A n=4, B n=5) and p-p38 (C, D n=6) normalized to 
untreated DCs (dotted line) from n ≥ 4 different donors. One-way ANOVA with Turkey’s posttest or Kruskal-Wallis 
with Dunn’s posttest. 
However, treatment of LPS with PSMα3 for 60 min showed a reduced 
phosphorylation of NF-κB (2.5±0.46 vs 2.26±0.46), which was not significant but 
observed for most donors (Figure 3-3 B). The analysis of p-p38 in TLR4-stimulated 
moDCs upon PSMα3 treatment showed a slight reduction of phosphorylation after 30 
min (2.95±0.4 vs 2.76±0.31) and 60 min (1.9±0.16 vs 1.58±0.13), this was observed 
for most of the analyzed donors after 30 min and all the analyzed donors after 60 min 
(Figure 3-3 C, D). The analysis of these signaling pathways indicates an effect of 
PSMα3 on the phosphorylation of both NF-κB and p38 in TLR4-treated moDCs, 
which may be responsible for the observed changes in DC maturation and cytokine 
production.  
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3.4 PSMs reduce antigen uptake by moDCs 
The main function of DCs in the periphery is to take up antigen for presentation and 
activation of T cells (Trombetta & Mellman, 2005). The preferred routes of antigen 
uptake by iDCs are via clathrin-mediated endocytosis and macropinocytosis, 
whereas mDCs lose most of their endocytic capacity and retain antigen uptake only 
by clathrin-mediated endocytosis (Burgdorf et al., 2007; Platt et al., 2010). To 
elucidate whether PSMs have an effect on this pivotal task, moDCs were treated with 
Sa lysate or LPS in the presence and in the absence of PSMα3 or with only PSMα3 
for 3 h (Figure 3-4 A) or 24 h (Figure 3-4 B) and AlexaFluor647-labeled OVA uptake 
was assessed by flow cytometry analysis. 
 
Figure 3-4: PSMs areduce antigen uptake by moDCs (adapted from Richardson et al., 2018) 
MoDCs were treated with Sa lysate (Sa) or LPS with, and without, PSMα3, or with only PSMα3 for 3 h (A) or 24 h 
(B). Subsequently, moDCs were incubated with AlexaFluor647-labeled OVA at 37°C or on ice for 30 min. OVA 
uptake was assessed in CD11c+HLA-DR+ moDCs by flow cytometry. The histogram overlays show the MFI of 
original data from one representative for 3 h (A) or 24 h (B). The bar graphs show the normalized MFI as fold 
change to untreated cells (n ≥ 3, performed in triplicates, mean ± SEM). One-way ANOVA with Turkey’s posttest 
or Kruskal-Wallis with Dunn’s posttest. 
To exclude unspecific binding, the incubation of moDCs with OVA was performed on 
ice. This prevents the mobilization and remodeling of the actin cytoskeleton, which is 
required for antigen capture via clathrin-mediated endocytosis and micropinocytosis 
(West et al., 2004). As expected, no OVA signal was detected for moDCs incubated 
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on ice (Figure 3-4 A, B). Maturation of moDCs via stimulating TLR2 with Sa lysate or 
TLR4 with LPS leads to a reduced uptake of OVA already after 3 h by ∼44% or ∼31% 
(Figure 3-4 A), but also after 24 h by ∼68 or ∼63%, respectively (Figure 3-4 B), 
confirming the loss of endocytic capacity of mDCs. Treatment of iDCs with PSMα3 
alone led to a reduction of OVA uptake by ∼18% after 3 h (p<0.319) (Figure 3-4 A) 
and by ∼48% after 24 h (***p<0.0003) (Figure 3-4 B) indicating that PSMα3 affects 
antigen uptake of iDCs. The analysis of PSMα3 treatment in mDCs revealed no 
difference in TLR2-treated cells after 3 h and only a slight increase in TLR4-treated 
cells (Figure 3-4 A). However, after 24 h the co-treatment of TLRLs and PSMα3 
showed a further reduction of OVA uptake by ∼11% and ∼8% respectively compared 
to only TLRL-treated moDCs (Sa p=0.1407, LPS p=0.8459), which is shown for Sa 
cell lysate in the histogram overlay of the original data (Figure 3-4 B). In summary, 
PSMs affect antigen uptake by reducing OVA uptake especially by iDCs after 3 h and 
24 h, but also slightly decreasing that of mDCs after 24 h.  
3.5 PSMs form transient pores into the moDCs membrane 
thereby entering the cell  
PSMs have cytolytic activity with the ability to form transient pores into the cell 
membrane. This feature not only allows PSMs to lyse human immune cells but also 
to enter the cytosol of cells (Armbruster et al., 2016b). To investigate whether PSMs 
can form transient pores in the membrane of human moDCs, or if these peptides are 
internalized via an active process of antigen uptake, cells were treated with either Sa 
lysate or LPS in the presence and in the absence of PSMα3 for 24 h. Thereafter, 
moDCs were incubated with fluorescently-labeled PSMα2 and AlexaFluor647-labeled 
OVA peptides and cells were analyzed by flow cytometry or multispectral imaging 
flow cytometry (Figure 3-5 A, B). Despite the maturation state of moDCs, PSMα2-
FITC was detected in all uniquely treated and analyzed moDCs. Whereas a slightly 
higher MFI was detected in TLR2-treated cells and a slightly minor MFI in TLR4-
treated moDCs compared to iDCs, there was no difference between TLRL compared 
to TLRL and PSMα3 treatment (Figure 3-5 A). PSMα2-FITC was also detected, 
although reduced by ∼54% (p=0.0003) in cells incubated on ice, indicating that 
uptake of PSMα2-FITC is not entirely dependent on actin rearrangement (Figure 3-5 
A). When analyzing PSMα2-FITC internalization and localization via multispectral 
imaging flow cytometry, the observed quantitative data from the flow cytometry 
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analysis were confirmed. PSMα2-FITC was detected in moDCs regardless of the 
treatment (Figure 3-5 B).  
 
 
Figure 3-5: PSMs penetrate the moDC membrane via transient pore formation (adapted from Richardson 
et al., 2018) 
(A, B) MoDCs were treated with Sa lysate (Sa) or LPS with, and without, PSMα3 for 24 h. Subsequently, moDCs 
were incubated with AlexaFluor647-labeled OVA and FITC-labeled PSMα2 at 37°C or on ice for 30 min. The 
signal of PSMα2 FITC was assessed in CD11c+HLA-DR+ moDCs as MFI by flow cytometry (A) or by imaging flow 
cytometry (B). (A) The histogram overlay shows the MFI of original data from one representative. The histograms 
show the normalized MFI as fold change to untreated cells (n ≥ 5, performed in triplicates, mean ± SEM). (B) The 
localization of PSMα2-FITC in CD11c+HLA-DR+ moDCs was analyzed by multispectral imaging flow cytometry 
(one representative experiment of n = 3 independent experiments; mean ± SEM). Representative bright field (BF) 
and fluorescence images of moDCs are shown for the different treatments. (C, D) MoDCs were either not treated 
(unst.) or incubated with 1% Triton X-100, 2% DMSO, PSMα3 (2.5 µM, 5 µM, 7.5 µM or 10 µM), 10 µM PSMα2, 
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10 µM δ-Toxin or 5 µg/mL OVA for 10 min. (C) LDH release was determined in the cell culture supernatants (one 
representative experiment of n = 3 independent experiments; mean ± SEM). (D) The treated cells were used to 
assess cell death of moDCs by flow cytometry using 7-AAD. ****p < 0.0001, one-way ANOVA with Turkey’s 
posttest or Kruskal-Wallis with Dunn’s posttest. 
The fluorescently labeled PSMα2 peptides were detected as spots close to the 
membrane when incubated at 4°C or 37°C, and colocalized with AlexaFluor647-
labeled OVA when incubated at 37°C. As PSMα2 was detected inside the cells when 
incubated at 4°C, its internalization is independent of actin rearrangement (Figure 3-
5 B). To further analyze how PSMs enter moDCs, pore formation was assessed by 
measuring the release of L-lactate dehydrogenase (LDH) in the supernatants of PSM 
treated moDCs. LDH is a cytosolic enzyme and only present in the supernatant when 
released via pores in the cell membrane. This is often used to measure cellular 
cytotoxicity. Triton X-100, a detergent capable of lysing cells was used as positive 
control, as it disrupts the cell membrane. δ-Toxin, a peptide belonging to the family of 
PSM peptides was also used as positive control, as it was shown to form transient 
pores (Pokorny et al., 2006). Neither untreated cells nor cells treated with OVA nor 
DMSO, which was used to dissolve PSM peptides, released LDH into the 
supernatants (Figure 3-5 C). However, treatment with PSMα2, δ-Toxin or PSMα3 
significantly induced the release of LDH, for PSMα3 in a concentration-dependent 
manner (Figure 3-5 C). Measuring cell viability by flow cytometry showed that aside 
from Triton X-100, the various treatments had no effect on the viability of moDCs 
(Figure 3-5 D). This indicates that PSMs are able to enter moDCs, most likely by 
transient pore formation and are located close to the membrane or colocalized with 
OVA inside the cell without having cytolytic effects.  
3.6 Th1 cell differentiation induced by TLRL-treated moDCs is 
suppressed by PSMs 
DCs play a crucial role in the activation of naïve T cells thereby shaping the immune 
response by driving differentiation into the distinct effector T-cell subsets (Mellman & 
Steinman, 2001). Specific transcription factors, called master regulators of the T 
helper (Th) lineages, control the differentiation of these T-cell subsets, with T-bet 
important for Th1 cell, GATA-3 for Th2 cell, RORγt for Th17 cell, and FoxP3 for Treg 
differentiation (Li et al., 2014). 
To address whether PSMs also have effects on the adaptive immune response by 
modulating DC functions, moDCs were treated with Sa lysate or LPS in the presence 
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and in the absence of PSMα3 for 24 h. After, treated moDCs were co-cultured with 
naïve CD4+ T cells for 3 d and Th subsets were analyzed by flow cytometry (Figure 
3-6 A). Treatment of moDCs with PSMα3 alone had no effect on Th1 polarization and 
showed only a slight increase in Th2 differentiation compared to untreated iDCs 
(Figure 3-6 B). TLRL-treated moDCs increased the frequency of both Th subsets; 
however, co-treatment with PSMα3 significantly reduced the priming of Th1 cells in 
TLR4, as well as TLR2-stimulated mDCs, characterized by less expression of the 
transcription factor T-bet (Figure 3-6 A, B). PSMα3 showed the same tendency for 
priming the Th2 cells by TLRL-treated moDCs with a slightly less GATA3 expression 
(Sa 1.32 vs. 1.1%, p = 0.27; LPS 1.25 vs. 1.1%, p = 0.8) (Figure 3-6 A, B). In 
contrast, no difference in the frequency of RORγt+ Th17 cells was observed when T 
cells were co-cultured with mDCs or PSMα3-treated mDCs (Figure 3-6 A, B).  
 
Figure 3-6: Th1 cell differentiation induced by TLRL-treated moDCs is suppressed by PSMs (adapted from 
Richardson et al., 2018) 
MoDCs were treated with Sa lysate (Sa) or LPS with, and without, PSMα3, or with only PSMα3 for 24 h. After, 
cells were co-cultured with CFSE-labeled naïve CD4+ T cells for 3 d. Th subsets were analyzed by flow cytometry; 
Th1 cells were characterized as CD3+CD4+T-bet+ T cells, Th2 cells were characterized as CD3+CD4+GATA3+ T 
cells, and Th17 cells were characterized as CD3+CD4+RORγt+ T cells. (A) Gating strategy with frequencies of the 
 Results  
 39 
three Th subsets in LPS or LPS with PSMα3 treated cells. (B) The bar graphs show the frequency of T-bet+ Th1, 
GATA3+ Th2, and RORγt+ Th17 cells of CD4+ T cells (one representative of n = 4 independent experiments 
performed in triplicates, mean ± SEM). ****p < 0.0001, one-way ANOVA with Turkey’s posttest or Kruskal-Wallis 
with Dunn’s posttest. 
Not only the interaction between DCs and T cells, but also the local cytokine 
environment control T-cell polarization. Th1 cells require IL-12 for their differentiation, 
which then predominantly produce IFN-γ, whereas Th2 cells depend on IL-4 and also 
mainly produce IL-4 and IL-13. Th17 cells are characterized as IL-17A producing 
cells and are induced among others by IL-6 (Li et al., 2014). To address whether 
PSMs have an effect on the cytokine environment in the DC-T-cell co-culture, 
supernatants were collected each day and analyzed by a bead-based cytokine array. 
TLRL-treatment induced the secretion of all analyzed cytokines after 1 d or 2 d 
(Figure 3-7). The analysis of the impact of PSMs on the effector cytokines of the 
different Th subsets showed a drastically decreased secretion of IFN-γ in TLR4-
stimulated cells when PSMα3 was present after 2-3 d; indications of this drastic 
decrease were observed after only 1 d (Figure 3-7 A). This was also observed in 
TLR2-stimulated cells after 2-3 d; although here the effect was not significant (Figure 
3-7 A). PSMα3 had no effect on the TLRL-induced secretion of IL-17A or IL-4 
(Figure 3-7 B, C).  
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Figure 3-7: PSMs modulate the cytokine milieu of the moDC-T-cell co-culture (adapted from Richardson et 
al., 2018) 
(A-I) MoDCs were treated with Sa lysate (Sa) or LPS with or without PSMα3 or with only PSMα3 for 24 h and co-
cultured with CFSE-labeled naïve CD4+ T cells for 3 d. Every day supernatants of the co-culture were collected 
and analyzed via a bead-based cytokine array to determine IFN-g (A), IL-17A (B), IL-4 (C), IL-13 (D), IL-2 (E), 
CD40L (F), TNF (G), IL-6 (H) and IL-12p70 (I) levels in the moDC-T-cell co-culture. (n ≥ 3 independent 
experiments performed in triplicates, mean ± SEM). *p < 0.05, or **p < 0.005, one-way ANOVA with Turkey’s 
posttest or Kruskal-Wallis with Dunn’s posttest.  
Co-treatment of moDCs with TLRLs and PSMα3, however, significantly increased the 
production of IL-13 in the co-culture, for TLR2 stimulated cells as early as after 1 d 
and in combination with LPS after 3 d (Figure 3-7 D). IL-2 and CD40L are key 
stimulators for the proliferation of immune cells. PSMα3 showed only a trend to 
increase IL-2 after 3 d compared to TLRL-stimulated cells, but had no effect on 
CD40L secretion (Figure 3-7 E, F). Further, PSMα3 completely inhibited the TLR4-
induced secretion of the pro-inflammatory effector cytokines TNF, IL-6 and IL12p70, 
which was observed at all the indicated times (Figure 3-7 G-I). TLR2-treated cells 
showed lower levels of TNF and IL-12p70, but here PSMα3 also completely inhibited 
the production at all times (Figure 3-7 G, I). TLR2-induced IL-6 production was also 
inhibited by PSMα3, but this effect was not significant and not as pronounced as in 
TLR4 stimulated cells (Figure 3-7 H). In summary, PSMα3 suppresses Th1 
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polarization by inhibiting the expression of T-bet and by completely blocking cytokine 
secretion of IL-12p70 and IFN-γ in LPS-treated cells; this is not only important for 
Th1 development but also for Th1 function. PSMα3 additionally inhibited the 
secretion of pro-inflammatory cytokines in the co-culture, which was also observed 
for moDC cytokine production and on the contrary increases the secretion of IL-13.  
3.7 PSMs increase the frequency of induced regulatory T cells 
with suppressive capacity 
It was previously shown that PSMs induce Treg proliferation and frequency upon 
priming mouse tDCs (Armbruster et al., 2016b; Schreiner et al., 2013). As PSMα3-
treated mDCs attenuated the priming of Th1 cells, the effect of PSMα3 on Treg 
priming was assessed. Therefore, moDCs were treated with Sa lysate or LPS in the 
presence or absence of PSMα3 for 24 h. These treated moDCs were then co-
cultured with naïve CD4+ T cells for 3 d or 4 d and iTregs were analyzed by flow 
cytometry, characterized as CD3+CD4+CD127-CD25hiCD45RA-FoxP3hi cell subset 
((Santegoets et al., 2015); Figure 3-8A). Whereas TLRL- or PSMα3-treatment of 
moDCs alone had no effect on iTreg priming compared to untreated cells after 3 d, 
combined treatment of DCs with Sa lysate with PSMα3 or LPS with PSMα3 showed 
a significantly higher frequency of iTregs (Figure 3-8 B). After 4 d TLRL- or PSMα3-
treatment of moDCs alone already showed an increased frequency of iTregs 
compared to untreated cells, however, combined treatment again showed an even 
higher significant increase of iTregs (Figure 3-8 A, B). Analysis of the proliferation 
capacity of iTregs induced by TLRL-treated or in combination with PSMα3-treated 
moDCs by CFSE staining showed that iTreg proliferation is increased in the presence 
of PSMα3 (Figure 3-8 C). 
Close analysis shows that PSMα3 modulates human mDCs to induce iTreg 
polarization and proliferation.  
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Figure 3-8: PSM peptides induce iTreg frequency and proliferation (adapted from Richardson et al., 2018) 
MoDCs were treated with Sa lysate (Sa) or LPS with, and without, PSMα3, or with only PSMα3 for 24 h. After, 
moDCs were co-cultured with CFSE-labeled naïve CD4+ T cells for 3 d or 4 d. iTregs were analyzed by flow 
cytometry and characterized as CD3+CD4+CD127−CD25hiCD45RA−FoxP3hi cells (A). The frequency of iTregs from 
CD4+ T cells (B) and the proliferation of iTregs (C) were determined by flow cytometry (n ≥ 5 performed in 
triplicates, mean ± SEM). *p < 0.05, **p < 0.005, or ****p <0.0001, one-way ANOVA with Turkey’s posttest or 
Kruskal-Wallis with Dunn’s posttest. 
To analyze whether these iTregs are functional and have suppressive capacity, iTregs 
were sorted after being primed by LPS and PSMα3-treated moDCs for 4 d. Tregs were 
sorted as live CD4+CD127-CD25hiCD45- cells and showed a purity of >99% after 
sorting (Figure 3-9 A). The purified iTregs were then co-cultured in different 
concentrations with CFSE-labeled CD4+ T cells (effector T cells; Teff), which were 
activated with anti-CD3/CD28 Dynabeads and proliferation of Teffs was analyzed after 
3 d. Teffs only, either activated with beads or not activated, served as control. 
Activated Teff cells only showed the maximal proliferation capacity in the experiment, 
whereas not activated Teff showed no proliferation at all (Figure 3-9 B). The 
proliferation of the Teff cells was significantly inhibited in a concentration-dependent 
manner, with the highest inhibition of ~38% at a ratio of 1:1 (Teff:iTregs), ~25% at a 2:1 
ratio (Teff:iTregs) and no significant but still a ~12% inhibition of the proliferation with a 
ratio of 4:1 (Teff:iTregs) (Figure 3-9 B). This shows that PSMα3-primed mDCs not only 
induce the frequency and proliferation of iTregs, but that these iTregs are functionally 
capable of inhibiting Teff cell proliferation. 
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Figure 3-9: PSMα3-treated mDCs induce iTregs with suppressive capacity (adapted from Richardson et al., 
2018) 
MoDCs were treated with LPS and PSMα3 for 24 h and co-cultured with naïve CD4+ T cells for 4 d. (A) iTregs were 
purified using an ARIA IIu cell sorter from BD. The upper panel shows the gating of the iTregs, which were sorted 
as CD4+CD127−CD25hiCD45RA− cells and the lower panel shows the re-analysis of the purified iTregs after sorting. 
(B) The purified iTregs were co-cultured with CFSE-labeled and CD3/CD28 Dynabeads activated CD4
+ T effector 
cells (Teff) and proliferation of the Teffs was assessed after 3 d by flow cytometry. The histogram overlay shows the 
proliferation peaks of Teffs only (black) or Teffs co-cultured together with iTregs in a ratio of 1:1 (red). The bar graphs 
show the division index of activated or not activated Teffs without or with the presence of iTregs in various ratios. (n 
= 3, performed in triplicates, mean ± SEM). *p < 0.05, or ***p <0.001, one-way ANOVA with Turkey’s posttest or 
Kruskal-Wallis with Dunn’s posttest. 
3.8  Induced regulatory T-cell polarization is mediated by PSMα3-
treated moDCs via direct cell interaction and upon 
production of soluble factors  
To investigate which mechanisms or factors are important for iTreg priming by PSMα3 
treated mDCs, naïve CD4+ T cells were co-cultured with differently treated moDCs. 
As described above, PSMα3-treated mDCs significantly increased the priming of 
iTregs compared to mDCs alone (Figure 3-10 A, B condition 1). First, to investigate 
whether soluble factors produced by mDCs are important for the priming, naïve T 
cells were co-cultured with iDCs adding medium from primed moDCs (conditioned 
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medium; Figure 3-10 A condition 2). The medium from LPS and PSMα3 primed 
moDCs showed a similar increase of iTregs as in condition 1, whereas the LPS 
conditioned medium showed no effect (Figure 3-10 B condition 2). This indicates 
that the medium from PSMα3-primed mDCs contains soluble factors necessary for 
iTreg priming. 
Next, to exclude soluble factors secreted by mDCs in the first 24 h (stimulation time), 
moDCs were treated with LPS or LPS and PSMα3 for 24 h, washed after the 
incubation time, re-seeded and cultured with naïve T cells for 3 – 4 d in fresh medium 
(Figure 3-10 A condition 3). These mDCs induced an even higher frequency of 
iTregs than mDCs without medium change, also with LPS-treated cells. Similarly, the 
combination with PSMα3 significantly increased the frequency of iTregs, suggesting 
that the interaction of mDCs and CD4+ T cells, as well as secreted factors upon the 
interaction of the two cell types are important for iTreg priming (Figure 3-10 B 
condition 3).  
Lastly, to address the impact of direct DC-T-cell interaction on iTreg priming, mDCs 
were fixed after treatment with LPS or LPS and PSMα3 for 24 h. The fixed moDCs 
were either cultured with naïve CD4+ T cells in fresh medium or in conditioned 
medium for 3 – 4 d (Figure 3-10 A condition 4). The co-culture of CD4+ T cells with 
fixed mDCs in fresh medium showed low frequencies of iTregs regardless of whether 
PSMα3 was present or not (Figure 3-10 B condition 4). Similar results were 
obtained when fixed mDCs were co-cultured with T cells in conditioned medium 
(Figure 3-10 B condition 4), showing that the direct and intact interaction of mDCs 
with naïve CD4+ T cells is crucial for iTreg polarization.  
To summarize these findings, direct interaction of PSMα3-treated mDCs and T cells 
is necessary for sufficient iTreg induction. Furthermore, soluble factors produced by 
moDCs upon the treatment with TLRLs and PSMα3 and/or after interaction with T 
cells, are essential.  
Several factors are known to induce iTreg priming, like TGF-β, IL-10, IL-2, and IDO 
(Raker et al., 2015; Rosenzwajg et al., 2015; Schmitt & Williams, 2013). To 
investigate whether cytokines produced by PSMα3-treated moDCs mediate iTreg 
priming, moDCs were treated with Sa lysate or LPS in the presence or absence of 
PSMα3 for 24 h. These treated moDCs were co-cultured with naïve CD4+ T cells for 
3 d and co-culture supernatants were analyzed over time for TGF-β, IL-10, and IL-2. 
Neither IL-10 nor TGF-β were increased in the co-culture of PSMα3-treated mDCs 
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with naïve CD4+ T cells, but rather decreased in the case of TLR4-treated cells 
compared to the co-culture with mDCs (Figure 3-10 C, D). Analysis of IL-2 
production in the co-culture revealed no difference after 1 d or 2 d, but a slight 
increase after 3 d (Figure 3-7 E). The secretion of cytokines important for Th priming 
however was almost completely inhibited in LPS and PSMα3 treated mDCs (Figure 
3-7).  
Lastly, examination of IDO secretion showed a noticeably increased production by 
LPS-treated moDCs in response to PSMα3 for both analyses (Figure 3-10 E) 
compared to LPS-treated cells alone. IDO was shown to be important for Treg 
differentiation from naïve T cells (Raker et al., 2015) and LPS treatment alone led to 
IDO secretion, which had been previously described (Salazar et al., 2017). IDO was 
not detected in Sa lysate-treated cells but slightly increased upon PSMα3 treatment, 
which however, was insignificant (Figure 3-10 E).  
 
 
Figure 3-10: PSMα3-treated mDCs induce iTregs by secretion of soluble factors and direct DC-T- cell-
interaction (from Richardson et al., 2018) 
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(A) The experimental setting in a schematic overview: T cells were co-cultured for 3 – 4 d (1) with mDCs (treated 
with LPS or LPS + PSMα3 for 24 h), with (2) untreated moDCs (iDCs) in the presence of conditioned medium 
from LPS or LPS + PSMα3 treated DCs, with (3) washed and re-seeded mDCs together with new medium or (4) 
with fixed moDCs together with either new medium or conditioned medium. (B) The frequencies of iTregs from 
CD4+ T cells from the experiments described in (A) (one representative of n ≥ 3 independent experiments 
performed in triplicates; mean ± SEM). (C, D) MoDCs were treated with Sa lysate (Sa) or LPS with, and without, 
PSMα3 for 24 h and co-cultured with CFSE-labeled naïve CD4+ T cells for 3 d. Every day supernatants of the co-
culture were collected and analyzed via a bead-based cytokine array to determine IL-10 (C) and TGF-β (D) levels 
in the moDC-T-cell co-culture. (n ≥ 3 independent experiments performed in triplicates, mean ± SEM). (E) MoDCs 
were treated with Sa or LPS with, and without, PSMα3 for 1 d or 2 d and cell culture supernatants were analyzed 
for IDO production by sandwich ELISA (n = 2 performed in triplicates; mean ± SEM). *p < 0.05, ***p < 0.001, or 
****p <0.0001, one-way ANOVA with Turkey’s posttest or Kruskal-Wallis with Dunn’s posttest. 
The most salient observation is that the induction of iTregs by PSMα3-treated mDCs is 
dependent on the direct interaction between DCs and T cells and on soluble factors 
produced by mDCs, most likely the enzyme IDO.  
 
In order to test if the secretion of IDO by PSMα3-treated moDCs really accounts for 
the increase in iTreg frequency, moDCs were pre-treated with the specific IDO 
inhibitor 1-Methyl-D-Tryptophan (1-DMT) prior to LPS or LPS and PSMα3 treatment. 
Again, mDCs were co-cultured with naïve CD4+ T cells and the iTreg frequency was 
determined. IDO inhibition surprisingly did not lead to diminished iTreg frequencies, 
but rather revealed even higher frequencies of iTregs independent of whether cells 
were treated with LPS with or without PSMα3 or not treated at all. Additionally, the 
difference in inducing iTregs between LPS-treated and LPS and PSMα3-treated 
moDCs was still significantly higher with PSMα3 (Figure 3-11 A). Considering this, 
the increased IDO production by PSM-treated mDCs seems not to be the cause for 
the increased iTreg polarization. 
 
 Results  
 47 
 
Figure 3-11: Inhibition of IDO and IL4-Rα has no impact on iTreg priming by PSMα3-treated mDCs (adapted 
from Richardson et al., 2018) 
MoDCs were pre-treated with either (A) the IDO inhibitor 1-Methyl-D-Tryptophan (1-DMT) or (B) a blocking 
antibody against the IL-4Rα subunit for 1 h prior the stimulation with LPS with, and without, PSMα3 for 24 h. 
MoDCs were then co-cultured with CFSE-labeled naïve CD4+ T cells for 3 d or 4 d and iTreg frequency was 
analyzed by flow cytometry. (one representative of n ≥ 3 independent experiments performed in triplicates; mean 
± SEM). *p < 0.05, *p < 0.005, or ****p <0.0001, one-way ANOVA with Turkey’s posttest or Kruskal-Wallis with 
Dunn’s posttest 
Additionally, it was proposed that IL-13 is able to induce iTreg differentiation 
(Skapenko et al., 2005). IL-13 was increased in the co-culture of PSM-treated mDCs 
with T cells (Figure 3-7 D). IL-13 and IL-4 exclusively bind to the IL-4Rα subunit 
(Skapenko et al., 2005); therefore to address whether IL-13 is the essential soluble 
factor in the co-culture leading to iTreg induction, moDCs were treated with various 
concentration of an inhibiting IL4Rα antibody prior to treatment with LPS or LPS and 
PSMα3. MDCs were afterwards co-cultured with naïve CD4+ T cells and the iTreg 
frequency was determined. Likewise, to the inhibition of IDO, the inhibition of the IL-
4Ra had no effect on the induction of iTregs by PSM-treated mDC (Figure 3-11 B). 
The inhibitory antibody had no effect on iTregs primed by untreated or LPS-treated 
moDCs; the frequencies were comparable to those of cells not treated with the 
antibody. However, when PSMα3 and LPS treated moDCs were pre-treated with the 
antibody, they induced a significantly higher iTreg frequency compared to PSM-
treated mDCs without antibody incubation. The frequency of iTregs was reduced with 
decreasing concentrations of the antibody (Figure 3-11 B), this suggests that the 
inhibition of the IL-4Ra leads to an even greater iTreg polarization and means that IL-
13 is not essential for iTreg priming by PSM-treated mDCs.  
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3.9 Induced regulatory T-cell polarization from CD4+ T cells of 
patients with autoimmune diseases upon interaction with 
PSMα3-treated mDCs 
The peptide toxin PSMα3 is able to modulate moDCs to prime iTregs. To address 
whether this feature can be used for therapeutic approaches in an autoimmune 
disease setting, moDCs from healthy donors were treated with LPS or LPS and 
PSMα3 for 24 h and co-cultured with CD4+ T cells from patients with 
spondyloarthritis. Spondyloarthritis is the name for a family of inflammatory rheumatic 
diseases with patients suffering from spondylitis and/or enthesitis, conditions which 
affect the spine and joints. Especially pro-inflammatory Th1 and Th17 cells are 
increased in these diseases (Smith & Colbert, 2014; C. Wang et al., 2015). 
The co-culture of PSMα3-treated mDCs from healthy donors with patient CD4+ T 
cells showed, as already described above for T cells from healthy donors, that 
PSMα3 significantly increased the capacity of LPS-treated moDCs to induce iTregs 
compared to LPS-treated moDCs (Figure 3-12 A). However, PSMα3 had no effect 
on the polarization into the different Th subsets from T cells from spondyloarthritis 
patients (Figure 3-12 A). The analysis of an autologous setting for better therapeutic 
applicability with moDCs and T cells from the same patient showed similar but not 
significant results (Figure 3-12 B). 
 
Figure 3-12: PSMα3-treated mDCs increases iTreg frequency from CD4
+
 T cells of spondyloarthritis 
patients (from Richardson et al., 2018) 
(A) Allogenic T-cell assay: MoDCs from healthy donors were treated with LPS with, and without, PSMα3 for 24 h 
and co-cultured with CFSE-labeled CD4+ T cells from patients with spondyloarthritis for 3 d or 4 d. The different T 
cell subsets were analyzed by flow cytometry. The graph shows the frequency of the T-bet+ Th1, GATA3+ Th2, 
RORγt+ Th17 cells and CD3+CD4+CD127−CD25hiCD45RA−FoxP3hi iTregs from CD4
+ T cells (n = 6 patients; mean 
± SEM). *p < 0.05, one-way ANOVA with Turkey's posttest or Kruskal-Wallis with Dunn's posttest. (B) Autologous 
T-cell assay: MoDCs from spondyloarthritis patients were treated as described in (A) and co-cultured with CFSE-
labeled CD4+ T cells from the same patients. CD3+CD4+CD127−CD25hiCD45RA−FoxP3hi iTregs were analyzed by 
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flow cytometry. The graph shows the frequency of iTregs as fold change from LPS-treated cells of 4 different 
spondyloarthritis patients. Unpaired student's T-test. 
In summation, PSMα3-treated mDCs also lead to iTreg polarization from CD4
+ T cells 
in allogenic and autologous inflammatory disease settings. Induction of tolerogenicity 
by PSMs being feasible in a clinical setting indicates their potential for DC therapy in 
chronic inflammatory diseases. 
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4. Discussion 
DCs not only initiate acute inflammatory responses but also maintain self-tolerance 
(Collin & Bigley, 2018). Various pathogens and tumors are able to modulate DC 
function and thus escape the immune response (Maldonado & Andrian, 2010; 
Ouyang et al., 2011). Sa is a major human pathogen and a leading cause of 
morbidity and mortality induced by a wide variability of secreted or cell surface-
associated virulence factors (Coates et al., 2014; DuMont & Torres, 2014; M. Miller et 
al., 2009; Peschel & Otto, 2013). The Sa PSMs are short cytolytic peptide toxins 
produced by highly virulent Staphylococci that greatly contribute to their 
pathogenesis and are capable of lysing many eukaryotic cell types. Sa PSMs are 
also capable of stimulating and modulating inflammatory responses. (Chatterjee et 
al., 2013; DuMont & Torres, 2014; Grumann et al., 2014; M. Miller et al., 2009; 
Peschel & Otto, 2013). PSMα peptides particularly harbor essential functions and are 
the most potent PSMs with regard to cytolysis and have been shown to modulate 
immune cell functions, e.g. that of DCs (Cheung et al., 2014; Peschel & Otto, 2013; 
Schreiner et al., 2013; R. Wang et al., 2007). It was previously shown that PSMs 
modulate mouse DCs and have the ability to impair their protective functions in the 
immune system. However, the impact of Sa PSM peptides on human DCs was 
hitherto unknown. In this study, the effect of PSMα3 on human moDC functions and 
the hence resulting T-cell response was assessed. 
4.1 PSMs enter human moDCs via pore formation 
Pore-forming toxins (PFTs) represent the largest class of bacterial toxins and are 
important virulence factors (M. R. Gonzalez et al., 2007). Sa produces many 
virulence factors including PFTs divided into three classes: α-hemolysin, PSMs, and 
bicomponent leukocidins (Blake et al., 2017). When analyzing PSMα2 uptake, the 
peptide was detected in moDCs when incubated at 37°C, as well as on ice. This was 
further confirmed with imaging flow cytometry that gave additional spacial information 
regarding the location of PSMs, which were observed as spots either close to the 
moDC membrane or colocalized with OVA inside the cells. The treatment of moDCs 
with different PSM peptides, like PSMα2, PSMα3 (in varying concentrations), or δ-
Toxin led to a concentration-dependent LDH release into the supernatant, without 
leading to cell lysis.  
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The presence of PSMα2 inside moDCs when incubated at 4°C indicates that its 
uptake does not rely on actin remodeling, which is necessary for active antigen 
uptake (West et al., 2004). PSMs rather form transient pores into the moDC cell 
membrane, as LDH, a cytosolic enzyme, which is only present in the supernatant 
when released via pores (Leroueil et al., 2007) was detected in the supernatants. 
This correlates with previous findings that showed δ-Toxin forms receptor-
independent short-lived transient pores (Otto, 2014; Pokorny et al., 2002). PSMs also 
form receptor-independent transient pores into membranes, thereby gaining access 
to the cytosol, which was shown for neutrophils (R. Wang et al., 2007), and DCs 
(Armbruster et al., 2016b), but in the case of DCs without cell lysis. The cytolytic 
activity of PFTs is mediated by pore formation in the membrane leading to an efflux 
of important molecules. PFTs from Sa either mediate lysis in a receptor-dependent 
manner and subsequent formation of pores, like α-hemolysin and bicomponent 
leukocidins; or in a receptor-independent fashion by attaching to the membrane, 
disintegration and short-lived pore formation (Otto, 2014). Therefore, PSMs 
presumably also form short-lived pores in the membranes of human moDCs and 
work similarly as Sa δ-toxin. It is, however, not clear why PSM peptides lyse 
neutrophils but show no cytolytic effects on DCs. One possible explanation could be 
a different composition and integrity of the cell membranes of neutrophils and DCs. 
The lipid composition of biomembranes is unique and enables various functionalities 
of cells and cell organelles depending on their functions (van Meer et al., 2008), 
whereas the integrity determines the fate of cells (Y. Zhang et al., 2018). The ability 
of PSM peptides to lyse neutrophils was inhibited in the presence of human serum 
and its comprised lipoproteins, which directly interacted with PSMs (Surewaard et al., 
2012). All mammalian sera contain lipoproteins (Chapman, 1986). Fetal bovine 
serum was used as medium supplement in this study, as well as when mouse DCs 
were analyzed (Armbruster et al., 2016b; Schreiner et al., 2013). This might explain 
why PSM peptides were not able to lyse DCs, as they were treated in the presence 
of serum lipoproteins. Whether PSMs are able to lyse human and mouse DCs in the 
absence of lipoproteins must be conducted in another study by treating the cells 
without using FBS-supplemented medium.  
The fluorescently-labeled PSMα2 peptides were either localized as spots close to the 
membrane or in the cytosol overlapping with the model antigen OVA when incubated 
at 37°C. If this colocalization of the two peptides implies that PSMs are inside the 
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phagosome, it must be further confirmed by investigating endosomal markers, like 
Lamp1 (Cook et al., 2004). The analysis of PSM localization in mouse DCs also 
showed spots close to the membrane and revealed that the peptide colocalized with 
p38, as well as with its phosphorylated form (Armbruster et al., 2016b), suggesting 
that PSMα2 is present in the cytosol as p38 is located in the cytoplasm and not in 
subcellular fractions (Ben-Levy et al., 1998; Roux & Blenis, 2004). This supports the 
observation that PSMs are located in the cytosol of human moDCs. The overlapping 
of PSMs and p38 further indicated direct interaction of the two. Molecularly, PSMα3 
enhanced the activation of the p38-cAMP response element-binding (CREB) protein 
pathway upon TLR ligation, which consequently diminished pro-inflammatory 
cytokine production but induced IL-10 secretion by mouse BM-DCs (Armbruster et 
al., 2016b). In human moDCs, this activation was not detected but rather a reduced 
phosphorylation of p38 and NF-κB. Instead of an induction of IL-10, a diminished 
secretion was observed, as well as for IL-12 and TNF, which was similar in the 
mouse. Whether PSMs interact with p38 in human moDCs remains elusive. The 
modulation of certain host’ pathways by PFTs is common; among them are the p38, 
c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK)/ 
mitogen-activated protein kinase (MAPK) pathways, which are the main mediators of 
defense pathways (Los et al., 2013). Hence, it is not surprising that these signaling 
pathways are modulated as mechanisms to evade the host immune response: a 
common function of PFTs (Los et al., 2013; Yoong & Pier, 2012). It was further 
demonstrated that PSMα peptides are important for phagosomal escape due to their 
lytic function, another immune evading mechanism for cytoplasmic replication of the 
pathogen (Grosz et al., 2014). PSMs presumably exert their cytolytic function 
primarily inside the cell and are capable of lysing neutrophils after phagocytosis 
(Surewaard et al., 2013). Still, the presence of PSMs inside DCs did not lead to cell 
death.  
The pore-forming capability of PSMα peptides is important for Sa pathogenesis; not 
only are these peptides able to lyse certain immune cells, like erythrocytes, 
monocytes, and human neutrophils (Cheung et al., 2011; 2010; Forsman et al., 2012; 
Kretschmer et al., 2010; R. Wang et al., 2007), but they also penetrate immune cells 
to enter the cytosol of cells, like DCs, to modulate signaling pathways (Armbruster et 
al., 2016b; R. Wang et al., 2007) and escape phagosomal degradation (Grosz et al., 
2014). PSMs are therefore essential for Sa survival, where α-type PSMs play a 
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crucial role as these peptides are highly cytolytic, with PSMα3 being by far the most 
active (Geiger et al., 2012; Otto, 2014) and developing drugs that target these 
peptides might attenuate Sa virulence.  
4.2 PSMs modulate DC functions thereby inducing a tolerogenic 
phenotype  
DCs initiate all antigen-specific immune responses and are therefore master 
regulators in the immune system by linking the innate with the adaptive immune 
response. Not only do they activate the immune system in response to foreign 
antigens, but they also avoid responses to self antigens, thereby maintaining self-
tolerance and preventing autoimmunity (Mellman, 2013). In order to successfully 
activate T cells, DCs must undergo maturation, including the upregulation of 
maturation markers, costimulatory, as well as coinhibitory molecules (Banchereau et 
al., 2000). Upon activation and maturation, DCs express cytokines, essential for T-
cell activation and priming (Blanco et al., 2008b). Here, almost all investigated 
functions of moDCs to induce immunity against inflammatory stimuli were 
counteracted by PSMs. 
The treatment of human moDCs with TLRLs showed a decrease of antigen uptake, 
indicating DC maturation of moDCs after TLR stimulation. The treatment with PSMα3 
of either iDCs or mDCs showed reduced antigen uptake, revealing that PSMα3 
affects moDCs in their capacity to take up antigens independently of their maturation 
state. The analysis of DC surface molecule expression showed that not only moDCs 
treated with TLRLs did undergo maturation but also when co-treated with PSMα3. 
PSMα3, however, changed the surface molecule expression of TLRL-treated moDCs 
by enhancing early costimulatory molecule and HLA-DR expression, but inhibiting 
CD80, CD40, and PD-L1 upregulation upon TLR4 stimulation. The treatment with 
PSMα3 further impaired pro-inflammatory, as well as anti-inflammatory cytokine 
secretion by TLR4-treated moDCs. This impairment might be explained by the 
prevented activation of the NF-κB, as well as the p38 MAPK signaling pathway in 
TLR4-treated moDCs indicated by diminished phosphorylation of the two molecules. 
These effects of PSMα3 on moDCs show that the Sa peptide toxin targets DC 
maturation and thereby dampens the immune response (Figure 4-1). 
In the periphery iDCs preferentially take up antigen via clathrin-mediated endocytosis 
and micropinocytosis, whereas mDCs retain uptake only via clathrin-mediated 
endocytosis (Burgdorf et al., 2007; Platt et al., 2010; Trombetta & Mellman, 2005). 
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Stimulation with TLRLs and the thus resulting reduced antigen uptake is due to 
maturation of moDCs, which loose most of their endocytic capactity, with only 
clathrin-mediated endocytosis remaining. The diminished antigen uptake of mDCs 
upon PSMα3 treatment indicated that the peptides target clathrin-mediated 
endocytosis, thereby further reducing moDCs endocytic capacity. Analysis of PSM-
treated mouse BM-DCs also revealed reduced clathrin-mediated endocytosis that 
resulted in less efficient antigen presentation leading to the observed reduced T-cell 
activation, whereas there were no effects on macropinocytosis and phagocytosis 
(Schreiner et al., 2013). This supports the generated results on human moDCs. The 
reduction of antigen uptake as possible immune evasion strategy is not specific for 
Sa; Yops, virulence factors of Yersinia enterocolitica, also inhibit OVA uptake 
(Autenrieth et al., 2007) and antigen degradation (Adkins et al., 2008). Another 
example is Salmonella typhimurium, which is further able to impair antigen 
presentation by DCs (Tobar et al., 2004). This impairment of antigen uptake and 
presentation by DCs shows that it is commonly advantageous for various bacteria as 
evasion strategy to ensure survival and dissemination. Antigen processing and 
presentation of human moDCs affected by PSMα3-treatment was not assessed and 
must be further investigated. This could be addressed by analyzing antigen 
processing with OVA-DQ, a self-quenching conjugate of OVA that is detected upon 
degradation (Adkins et al., 2008) or by using OVA-specific T cells (N. S. Wilson et al., 
2004) to compare T-cell activation upon interaction with untreated or PSMα3-treated 
moDCs.  
For a sufficient T-cell activation, the interaction of costimulatory molecules and their 
ligands is required. PSMα3 affected surface molecule expression of moDCs by 
inhibiting the costimulatory molecules CD80 and CD40, and also the coinhibitory 
molecule PD-L1. This was in accordance with the inhibited CD40 expression in 
mouse BM-DCs upon PSM-treatment, which further impaired the expression of 
CD54. On the contrary, CD80, MHC II, and CD86 expression was increased upon 
PSMα3-treatment, another similarity found in human moDCs (Armbruster et al., 
2016a). The aforementioned results show that surface molecule expression of both 
human and mouse DCs was altered by PSMs. Other pathogens and their secreted 
virulence factors also have effects on the surface molecule expression of DCs. 
Cholera toxin in combination with LPS is able to induce CD80 and CD86 expression, 
but decreases that of CD40 and CD54 by DCs, which modulates DC cell activation 
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and thereby promotes Treg induction (Lavelle et al., 2003). This is in part consistent 
with the effects on the studied human moDCs and the thereby responding T-cell 
activation.  
Not only surface molecule expression is induced by maturation, but also cytokine 
production (Hackstein & Thomson, 2004), which is completely prevented by PSMα3 
treatment. Mechanistically, the inhibition of TNF production, which among others 
regulates CD40 expression, upon synergistic treatment with TLRLs and PSMα3 
could explain the impaired up-regulation of CD40. This correlates with the previous 
observed downregulation of the CD40/CD40L pathway upon TNF blockade (Danese 
et al., 2006). NF-κB, as well as p38 activation is necessary for DC maturation 
including upregulation of CD80, CD86, and CD40, and is further important for 
cytokine production mediated by TLR signaling (Ardeshna et al., 2000; Dalod et al., 
2014; Kaisho & Akira, 2001). Simultaneous treatment of moDCs with TLRLs and 
PSMα3 did not show activation by phosphorylation of these molecules. Prevented 
activation of NF-κB and p38 corresponds with the abrogated CD40 and CD80 
expression and also with impaired cytokine secretion, however, does not explain the 
enhanced early costimulatory molecule expression. Mouse BM-DCs in contrast 
showed a greater activation of these signaling pathways after PSM-treatment thereby 
having similar effects on pro-inflammatory cytokine secretion and surface molecule 
expression (Armbruster et al., 2016a; Armbruster et al., 2016b; Schreiner et al., 
2013). This contrast might be due to species-specificity and indicates that different 
signaling pathways with possible similar outcomes might be regulated differently. 
TLR4-treated moDC function was more affected by PSMα3 incubation, suggesting 
that PSMα3 prevents TLR4-activation either extracellularly and/or intracellularly. 
Direct extracellular interaction of PSMα1–3 with TLR4 was shown to prevent binding 
of HMGB1 to TLR4 and thus downstream activation of NF-κB (Chu et al., 2018). This 
might explain the inhibited CD40 and CD80 expression, as well as the impaired 
cytokine production in TLR4-treated moDCs in the presence PSMα3. The Sa-derived 
peptide toxins were also detected inside DCs and colocalized with p38 thereby 
modulating this signaling pathway (Armbruster et al., 2016b). It is therefore not 
known if the greater effects on TLR4-treated moDCs is mediated by direct interaction 
of PSMα3 with the signaling molecules or also by blocking binding of LPS to TLR4, 
thereby preventing activation of the signaling cascade (Chu et al., 2018). Albeit 
PSMs dramatically changed the cytokine secretion pattern of mouse BM-DCs upon 
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TLR2 stimulation via the activation of NF-kΒ, p38, and ERK. This also led to an 
inhibited pro-inflammatory cytokine production of TNF, IL-6, and IL-12, however, 
induced the secretion of the anti-inflammatory IL-10 (Armbruster et al., 2016b; 
Schreiner et al., 2013). This differs to that found in human moDCs, which again might 
be due to differences in the species. The pro-inflammatory immune response 
implemented by the secretion of TNF plays a significant role in the clearance of Sa 
(Hultgren et al., 1998), therefore inhibiting cytokine production additionally is 
beneficial for pathogen survival. Again, targeting the MAPK signaling pathways is not 
specific for Sa PSM peptides. Other virulence factors, like YopJ from Yersinia 
pseudotuberculosis inhibits the phosphorylation of p38 and JNK thereby preventing 
the production of TNF in macrophages (Palmer et al., 1998). In addition, YopP from 
Yersinia enterocolitica not only suppresses TNF and IL-12 secretion, but also IL-10 
production by DCs (Erfurth et al., 2004). Many bacteria evade the host immune 
response by manipulating signaling pathways, like the NF-kΒ-, MAPK-, 
phosphatidylinositol 3-kinase-, and p21-activated kinase pathways (Krachler et al., 
2011). Targeting DC functions is an effective evasion strategy by pathogens to 
prevent inflammation and allowing uncontrolled spreading of the pathogen. Several 
groups described the induction of tDCs by pathogens (Couper et al., 2008; DePaolo 
et al., 2008; McGuirk et al., 2002). NF-κB inhibition favors an immature or tolerogenic 
DC phenotype, which stimulates the expansion of Foxp3-expressing Tregs 
(Iruretagoyena et al., 2006; Martin et al., 2007; Raker et al., 2015; Thompson et al., 
2004). Further, also other pathways and proteins, like p38 MAPK, JNK, ERK1/2 and 
IDO are differently regulated in tDCs compared to cDCs, with p38 MAPK and NF-κB 
inhibition leading to markedly down-regulated IL-12 production in cDCs after LPS 
treatment (Dáňová et al., 2015). This might molecularly explain the observed 
tolerogenic phenotype of human moDCs after synergistic treatment with TLRLs and 
PSMα3. The entire molecular mechanism however is still unclear and has to be 
further investigated to explain all the observed effects of PSMs on DC functions, 
which might help to better understand and control Sa pathogenesis. 
4.3 The PSM-primed tDCs induce iTreg differentiation and inhibit 
Th1 polarization  
Upon activation by DCs, CD4+ naïve T cells differentiate into different T effector cell 
subsets with distinct functions important for regulating immune responses (Tai et al., 
2018). The differentiation into Tregs regulates Th cell responses and is therefore 
 Discussion  
 57 
crucial for maintaining immune homeostasis (Shevach, 2009; Vignali et al., 2008; 
Zhou et al., 2009). As almost all functions of human moDCs were affected by PSMs, 
the subsequent T-cell activation and therefore the effect of PSMs on the adaptive 
immune response was assessed.  
PSMα3-treated mDCs suppressed Th1 polarization by inhibiting the expression of T-
bet and completely blocking cytokine secretion of IL-12p70 and IFN-γ in LPS-treated 
cells, not only important for Th1 development but also for their function. On the 
contrary, PSMα3-treated mDCs induced iTreg polarization and proliferation (Figure 
4-1). These iTregs were functionally capable of inhibiting Teff cell proliferation. When 
addressing the possible mechanism behind the induction of these iTreg the analysis of 
cytokine secretion in the moDC- T-cell co-culture showed that PSMα3 inhibited 
secretion of pro-inflammatory cytokines, which was also observed for moDC cytokine 
production. IL-10 production was also suppressed upon PSM-treatment by both 
mDCs and in the co-culture, indicating that this cytokine is not accountable for the 
induced Treg proliferation. Similar, the analysis of TGF-β levels in the co-culture 
showed that also this cytokine is not responsible for the here observed increased 
iTreg priming upon PSM-treatment of mDCs. In contrast, the secretion of the enzyme 
IDO was significantly increased by TLRL-treated moDCs, as well as that of the 
cytokine IL-13 in the moDC-T-cell co-culture in response to PSMα3. Neither IDO 
inhibition by 1-DMT (Agaugue et al., 2006), nor blocking of the IL-4Rα subunit, to 
which IL-13 and IL-4 exclusively bind to (Skapenko et al., 2005), prevented iTreg 
induction upon PSM-treatment, but rather enhanced it. Both, IDO and IL-13, 
therefore do not mechanistically contribute to the PSM-mediated Treg induction. One 
requirement of PSM-mediated Treg induction certainly is the direct DC-T-cell 
interaction; lacking this direct interaction abrogates iTreg polarization by PSM-treated 
mDCs.  
The here observed impairment of Th1 differentiation is consistent with findings of 
PSM-treated BM-DCs, which prevented Th1 priming, whereas that of Th17 cells was 
unaffected (Schreiner et al., 2013). The impaired ability to prime Th1 responses is 
not Sa-specific but was also shown for other infections, e.g. with Hepatitis C virus, 
leading to less IL-12p70 production by DCs (Kanto et al., 2004), which was likewise 
observed for human moDCs. Further, infection with the Hepatitis B virus 
compromises the antigen-presenting function of moDC with concomitant impairment 
of Th1 responses (Beckebaum et al., 2003). PSMs affected antigen uptake of human 
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moDCs, which might also lead to reduced antigen presentation, consequently leading 
to less Th1 polarization; this however remains to be shown. Not only the suppressed 
Th1 polarization but also the functional impairment by less effector cytokine secretion 
is critical in infections. Th1 and Th17 cells mediate protective CD4+ T-cell responses 
against Sa and Candida albicans due to the secretion of IFN-γ and IL-17 (Cho et al., 
2010; Lin et al., 2009; McLoughlin et al., 2008). Further, IFN-γ has an important 
protective role during systemic infection, by activating macrophages and neutrophils 
and thereby enhancing phagocytosis of the bacteria (Zhao & Tarkowski, 1995). This 
is in accordance with the impaired IFN-γ and IL-17A secretion in the moDC-T-cell co-
culture upon PSMα3 treatment. Impairment of inflammatory Th-cell responses due to 
the presence of PSM peptides might therefore lead to reduced clearance and is 
important for Sa immune escape, which was already observed in mice, where the 
mortality rate was higher when PSMα3 was expressed by Sa (R. Wang et al., 2007). 
The further observed induction of iTreg polarization and proliferation by PSMα3-
treated human mDCs is comparable to previous in vitro studies of mouse BM-DCs. 
PSM-treated BM-DCs had a tolerogenic phenotype and increased the priming of Tregs 
(Armbruster et al., 2016b; Schreiner et al., 2013). The balance between Tregs and Teffs 
is highly controlled, which is necessary during infections, on the one side to combat 
the infection, but on the other side to prevent immune pathologies (Belkaid, 2007). 
The induction of iTregs by a tolerogenic DC phenotype induced by the pathogen itself 
thus might lead to an enhanced immune evasion. A hallmark of tDCs is their 
immature phenotype characterized by low surface levels of MHC class II and 
costimulatory molecules. Phenotypically mature DCs mediate immunity, whereas it 
has been suggested that immature DCs, with a low MHC II and low costimulatory 
molecule and therefore poorly immunogenic phenotype, maintain tolerance 
(Kushwah et al., 2010; Ouyang et al., 2011; Raker et al., 2015; Villadangos & 
Schnorrer, 2007). The maturation state alone, however, does not define tDCs, as 
mature or semi-mature DCs were also found to induce tolerance (Raker et al., 2015; 
Villadangos & Schnorrer, 2007) and are capable of promoting Tregs and being 
superior in activating their suppressor function (Pletinckx et al., 2011; Spörri & Reis e 
Sousa, 2005). Although PSMα3 had little influence on most TLR-induced up-
regulated surface molecules, up-regulation of CD80, PD-L1, and CD40 was impaired, 
thereby preventing full DC-maturation. This modulation, however, did not keep the 
moDCs in an immature state, as surface molecule expression was definitely higher 
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than in unstimulated cells. The lack of CD40 expression on DCs was shown to be 
important for the generation of Tregs while suppressing primary immune responses 
(Quezada et al., 2004), which might also be the case here and lead to PSM-induced 
iTreg differentiation. Further, tDCs produce low amounts of pro-inflammatory cytokines 
(Manicassamy & Pulendran, 2011), which further supports the hypothesis that PSMs 
prime tDCs, as the secretion of all measured pro-inflammatory cytokines was 
prevented. T-cell differentiation is mainly controlled by cytokines that mediate 
polarizing signals (Campbell & Koch, 2011). Factors or molecules, like IL-10, TGF-β, 
retinoic acid, and IDO, are associated with Treg polarization (Kushwah & Hu, 2011; 
Raker et al., 2015). IL-10 production, however, was suppressed by human mDCs 
upon PSM-treatment, which is in contrast to the previously observed findings that 
PSMα3-induced mouse tDCs are characterized by the enhanced production of IL-10 
(Armbruster et al., 2016b; Schreiner et al., 2013). The suppression capacity of Tregs 
induced by PSM-primed mouse tDCs though was just partly dependent on IL-10 and 
TGF-β and suggested other mechanisms, like contact-mediated suppression 
(Schreiner et al., 2013). IL-10 therefore might be only important for the induction of 
Tregs but not for their functional tasks and further not important in PSM-induced iTreg 
induction by human DCs. Similarly, TGF-β that was reported to be required for Treg 
induction (Schmitt & Williams, 2013) also did not account for the observed iTreg 
induction also questioning its pivotal role in this process. It was further proposed that 
IL-13 is also able to induce iTreg differentiation (Skapenko et al., 2005), whose 
production was increased in the co-culture of PSM-treated mDCs with T cells. 
Blocking of its receptor, however, revealed that this was not the case for the here 
observed iTreg induction, suggesting that IL-13 is not essential for iTreg priming by 
PSM-treated mDCs. The enhanced Treg differentiation might be due to blocking the 
polarization of naïve T cells into Th2 cells and the plasticity of T cells allows the 
switch into one of the other subsets, in this case into Tregs (Zhou et al., 2009). The 
analysis of IDO showed a significantly higher secretion in PSMα3-treated mDCs. The 
adaptive immune response is modulated by IDO expression by DCs, which promotes 
immune suppression and tolerance (Bubnoff et al., 2011; Harden & Egilmez, 2012; 
Munn & Mellor, 2013). LPS treatment alone already induced IDO, which was recently 
reported (Salazar et al., 2017), however, IDO production by DCs was significantly 
enhanced upon PSMα3 treatment. Similar to blocking of the receptor for IL-13, IL-
4Rα, inhibition of IDO by the specific inhibitor 1-DMT (Agaugue et al., 2006) did not 
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prevent iTreg induction, arguing against IDO as an important factor for the increased 
iTreg differentiation by PSM-treated mDCs. The soluble factor or factors necessary for 
the here observed iTreg differentiation are not known so far, but some secreted factors 
have to be responsible as molecules secreted by DCs and upon DC-T-cell interaction 
were important. Apart from soluble factors, PSM-mediated Treg induction certainly is 
dependent on the direct DC-T-cell interaction, which is in accordance with previously 
reported findings (Corthay, 2009). Thus, PSMα3-treated mDCs induce Treg 
differentiation via direct DC-T-cell interaction, with presumably less CD40/CD40L 
interaction and less antigen presentation upon fewer uptake in combination with the 
absence of Th-priming cytokines and yet unknown DC-secreted factors. Various 
pathogens or pathogenic toxins are able to induce tDCs and subsequent Treg 
differentiation thus escaping the immune response (Maldonado & Andrian, 2010; 
Manicassamy & Pulendran, 2009; Ouyang et al., 2011). Candida albicans induces 
tDCs by modulating signaling pathways and enhancing IDO activation (Bonifazi et al., 
2009; Maldonado & Andrian, 2010). The Yersinia pestis virulence factor LcrV highly 
contributes to immune evasion by priming tDCs and promoting IL-10 production 
(DePaolo et al., 2008). Further, Fasciola hepatica- derived excretory-secretory 
products modulate BM-DCs by affecting maturation and their capacity to stimulate T-
cell responses. These products increased Treg polarization with increased IL-10 and 
TGF-β production (Falcón et al., 2010). Therefore, the priming of tDCs by PSMs as 
an effective evasion strategy to block inflammation and allowing uncontrolled 
spreading of the pathogen is not Sa-specific.  
Hence, PSMs are beneficial for Sa by preventing inflammatory responses by 
inhibiting Th1 polarization and priming iTregs, leading to uncontrolled spreading and 
immune evasion of Sa. On the contrary, inducing tolerance by priming tDCs thereby 
inhibiting inflammatory responses might be useful, especially in autoinflammatory 
diseases.  
4.4 PSMs as therapeutic approach in autoimmune diseases  
New therapeutic approaches for preventing or inhibiting hyper-reactive immune 
activations and responses like in autoimmune diseases, allograft rejection, or 
allergies are needed. Current therapies mainly use nonspecific systemic 
immunosuppressants, like glucocorticoids or cytostatics, which are associated with 
severe side effects (Maldonado & Andrian, 2010; Tamesis et al., 1996). DCs are 
regulators of the adaptive immune response and tolerance; therefore, the specific 
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generation and adoptive transfer of DCs, which are able to induce tolerance, into 
patients is attractive for clinical applications to enhance, maintain or restore 
immunological tolerance (Lutz, 2012). Thus, ex vivo generated tDCs are a new 
therapeutic option. PSMα3-treated mDCs induced iTreg priming, which was also 
observed in allogenic and autologous inflammatory disease settings, with either DCs 
generated from healthy donors or from the same patient. This showed that Sa-
derived PSMα3 has the potential to induce tolerogenic human DCs with the ability to 
prime iTregs indicating its potential for DC therapy in inflammatory diseases. Various 
pathogens escape the immune system by mechanisms exploiting Tregs (Belkaid, 
2007; Grainger et al., 2010; Mills, 2004). Pathogenic products and toxins, like here 
the Sa PSM peptides, are able to promote DC tolerogenicity thereby inducing iTreg 
differentiation, e.g. products from Fasciola hepatica, Schistosoma japonicum, 
Schistosoma mansoni, Bordetella pertussis, and Vibrio cholerae (Maldonado & 
Andrian, 2010; Ouyang et al., 2011). It is therefore not surprising that compounds, 
like cyclosporin, tacrolimus, voclosporin, and rapamycin are commonly used as 
immunosuppressive drugs to treat immune disorders and transplant rejection (Korom 
et al., 2009; Maldonado & Andrian, 2010). These therapeutic approaches, with the 
intake of such immuno-modulatory drugs are unspecific. They suppress the entire 
immune system and have serious side effects that lead to immunodeficiency 
(Maldonado & Andrian, 2010; Ouyang et al., 2011). DC vaccination strategies by 
applying tDCs are therefore an attractive alternative. Using DCs would lead to a more 
specific treatment option with less side effects as these are antigen-specific and only 
affect the auto-reactive inflammatory response (Maldonado & Andrian, 2010; Raker 
et al., 2015; Van Brussel et al., 2014; Yoo & Ha, 2016). The therapeutic potential of 
tDCs has been demonstrated in pre-clinical animal models of autoimmune diseases, 
like arthritis (van Duivenvoorde et al., 2007), EAE (Menges et al., 2002), and type 1 
diabetes (Feili-Hariri et al., 2002), as well as with in vitro generated human tDCs (Van 
Brussel et al., 2014). The generation of such tDCs, using different agents, like 
dexamethasone (Maldonado & Andrian, 2010; Piemonti et al., 1999) or vitamin D3 
(Maldonado & Andrian, 2010; Penna & Adorini, 2000), and their in vivo stability are 
critical parameters (Phillips et al., 2017). Previous clinical trials already revealed that 
DC administration is well tolerated (Dhodapkar & Steinman, 2002; Dhodapkar et al., 
2001; Raker et al., 2015; Steinman & Banchereau, 2007), which is pivotal for a 
sufficient therapy. Several clinical studies were conducted using tDCs for treating e.g. 
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rheumatoid arthritis (Thompson et al., 2004) or type I diabetes (Giannoukakis et al., 
2011), indicating that tDCs are a promising tool for therapy of autoimmune diseases.  
PSMα3, secreted by highly virulent CA-MRSA strains, might have the potential to 
induce stable human tDCs for therapeutic use in cellular therapy for autoimmune 
diseases. The stability of the PSM-induced tDCs, especially in the presence of 
inflammatory stimuli is crucial and has to be confirmed by all means before using the 
peptide for DC therapy. Lastly, it has to be investigated whether ex vivo generation of 
tDCs or direct administration of PSMs is more effective and if this approach is 
tolerable. While using PSM peptides for tDC induction seems to be a promising 
approach, remaining open questions have to be answered before the potential of 
PSMs can be exploited for DC therapy. 
 
Figure 4-1: Summary of the effects of Sa-produced PSM peptides on human moDCs (designed with 
BioRender – biorender.com) 
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Abbreviations 
1-DMT 1-Methyl-D-tryptophan  
BDCA Blood dendritic cell antigen 
BM-DCs Bone marrow-derived DCs  
CA-MRSA Community-associated Staphylococcus aureus 
CD Cluster of differentiation 
cDC Conventional DCs 
CFSE 
CREB 
Carboxyfluorescein succinimidyl ester  
cAMP response element-binding 
DAMPs Danger-associated molecular pattern 
DCs Dendritic cells 
FACS Fluorescence-activated cell sorting  
FoxP3 Forkhead box protein P3 
GATA3 GATA binding protein 3 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HLA-DR Human Leukocyte Antigen – DR isotype 
iDC Immature DCs 
IDO Indolamin-2,3-Dioxygenase  
IFN Interferon 
IL Interleukin 
ILT Immunoglobulin-like transcript 
IRAK Interleukin-1 receptor-associated kinase-like 
ISX Image-Stream mkII  
iTregs Induced Treg 
LDH Lactate dehydrogenase  
MAPK Mitogen-activated protein kinases 
mDC Mature DCs 
MHC Major histocompatibility complex 
MMR Macrophage mannose receptor 
moDC Monocyte-derived DC 
MyD88 Myeloid differentiation primary response 88 
NF-κB  
Nuclear factor kappa-light-chain-enhancer of activated B 
cells 
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NOD Nucleotide-binding oligomerization domain 
nTregs Natural Tregs 
OVA Ovalbumin 
PAMPs Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cell 
pDC Plasmacytoid DC 
PD-L Programmed death-ligand  
PFT Pore-forming toxin 
p-NF-κB  Phospho-NF-κB  
p-p38 Phospho-p38 
PRR Pattern recognition receptors 
PSM Phenol-soluble modulin 
RA Retinoic acid 
RORyt Retinoic acid receptor-related orphan receptor gamma 
Sa Staphylococcus aureus 
Sa lysate Staphylococcus aureus cell lysate 
STAT Signal transducer and activator of transcription 
TAP Transporter associated with antigen processing 
tDC Tolerogenic DC 
Teff Effector T cells  
TGF-β Transforming growth factor beta 
Th T helper cell 
TIR Toll/interleukin-1 receptor  
TIRAP Toll/interleukin-1 receptor domain-containing adapter protein 
TLR Toll-like receptor 
TLRL Toll-like receptor ligand 
TNF Tumor necrosis factor 
TRAF TNF receptor associated factor 
TRAM TRIF-related adaptor molecule 
Treg Regulatory T cell 
TRIF TIR-domain-containing adapter-inducing interferon-β 
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